

Nebraska State Immunization Information System

HL7 – 2.5.1 & Real-time Transfer Specification

GTS Version 8.0.1

Release Date: October 13, 2016

Contents

Latin de ation	_
Introduction	
The Health Level Seven (HL7) Standard	
Scope of this Document	
References	
VXUVXU	
ACK	
ACKADT	
QBP	
RSP	
Message Segments: Field Specifications and Usage	
HL7 Segment Structure	
Rules for Sending Systems.	
MSH	
PID	
PD1	
NK1	
PV1	
ORC	
RXA	
RXR	
OBX	
NTE	
Deduct From Inventory	
File Interchange between NESIIS and Outside Systems	22
Real-time Processing	
Real-time Process Message Types	26
VXU^V04^VXU_V04	27
Profile: Z22^CDCPHINVS	
QBP^Q11^QBP_Q11	27
Profile: Z34^CDCPHINVS	
Profile: Z44^CDCPHINVS	
RSP^K11^RSP_K11	
Profile: Z32^CDPHINVS	
Profile: Z31^CDCPHINVS	
Profile: Z33^CDCPHINVS	
Profile: Z23^CDCPHINVS	
Profile: Z42^CDCPHINVS	
Real-time Process Message Segments	
MSH Segment	
QPD Segment	
RCP Segment	
QAK Segment	
ERR Segment	
MSA Segment	
Appendix A HL7 Data Types	
CC Coded Element (most uses)	
CQ – Composite Quantity with Units	
CWE Coded with Eventions	
CWE – Coded with Exceptions	
DT_D – Date with Precision to Day	
DTM – Date/Time	
EI – Entity Identifier	
ERL – Error Location.	
FN – Family Name	
FT – Formatted Text (new)	
HD Hierarchic Designator	
ID Coded Values for HL7 Defined Tables	
IS Coded Values for User Defined Tables	

LA2 – Location with Address Variation 2	
MSG – Message Type	
NM Numeric	
PT – Processing Type	36
SAD – Street Address	
SI Sequence ID	37
ST String Data	37
TS – Time Stamp	
TS_M – Time Stamp with Optional Precision to the Day and No Time Zone	
TS_NZ – Time Stamp with Optional Precision to the Day and No Time Zone	
TS_Z – Time Stamp Requiring Time Zone	37
VID – Version Identifier	37
XAD – Extended Address	38
XCN Extended Composite ID Number and Name for Persons	38
XPN Extended Person Name	
XON – Extended Composite Name and ID Number and Name for Organizations	39
XPN_M – Extended Person Name – Maiden Name	39
XTN – Extended Telecommunication Number	39
Appendix B HL7 Tables	41
Sex	41
Event Type	41
Patient class	
Race	41
Acknowledgment Code	
Relationship	41
Financial class	42
Message Type	
Observation result status codes	
Query Priority	
Processing ID	
Version ID.	
Constrained	
Yes/No Indicator	
Accept/Application Acknowledgment Conditions	
Route of Administration.	
Administrative Site	
Ethnic Group	
Address Type	
Name Type	
Telecommunication use code	
Telecommunication equipment type	
Identifier Type	
Query Response Status	
Nationality	
Publicity Code	
Manufacturers of vaccines (code = MVX)	
County/parish (Nebraska & some surrounding counties)	
Completion status.	
Action code	
Message Structure	
Message Error Condition Codes.	
Assigning Authority	
Immunization registry status	
Error Severity	
Application Error Code	
Immunization Information Source	
Substance Refusal Reason	
Contraindications, Precautions	
Event Consequence	
Patient Registry Status	
Vaccine Funding Code	
V2.5.1 Value	

Evidence of Immunity	53
Serological Evidence of Immunity	
Reaction Codes	
Vaccine Group Code (WVGC)	53
Vaccine Trade Name (WVTN)	
CPT Codes (WCPT) and CVX Codes (292)	
Trade Name	58

Nebraska State Immunization Information System

HL7 – 2.5.1 & Real-time Transfer Specification

Introduction

The Nebraska State Immunization Information System (NESIIS) has made available an interactive user interface on the World Wide Web for authorized users to enter, query and update client immunization records. The Web interface makes NESIIS information and functions available by using any computer or tablet device with a connection to the Internet. However, some immunization providers already store and process similar data in their own information systems and may wish to keep using those systems while also participating in the statewide central repository. Others may have different billing needs and may decide they don't want to enter data into two diverse systems. NESIIS has been enhanced to accept HL7 Version 2.5.1 for immunization data. NESIIS also allows providers to submit client and immunization information using HL7 2.5.1 formatted QBP^Q11^QBP_Q11 Message (Query for Vaccination Record) and a VXU^V04 Message (Unsolicited Vaccination Update) and receive from NESIIS the resulting HL7 2.5.1 Response Message in real time. Specifications for HL7 2.5.1 Real-time start on page 25.

The Health Level Seven (HL7) Standard

The ANSI HL7 standard is widely used for data exchange in the health care industry. The full standard is quite lengthy, covering a variety of situations in patient care and health care finance and no single application is likely to use all of its content. The CDC has worked with HL7 developers to create a set of messages that permit exchange of immunization data. This document covers the subset of HL7 that will be used for client and immunization records exchanged between NESIIS and outside systems.

- The basic unit transmitted in an HL7 implementation is the **message**.
- Messages are made up of several **segments**, each of which is one line of text, beginning with a three-letter code identifying the segment type.
- Segments are in turn made up of several **fields** separated by a delimiter character, "|".

The details of how HL7 messages are put together, for NESIIS purposes, will be explained later in this document. The example above shows the essentials of what a message looks like. In this example, a message is being sent on behalf of Valley Clinic to NESIIS. The message consists of three segments. NOTE: Valley Clinic may or may not be the actual transmitter of the message. The transmitter of the message will be identified by NESIIS from log-in information and not from an HL7 message.

- The Message Header segment (MSH) identifies the owner VALLEY CLINIC (VALCLIN) of the information being sent and the receiver (NESHS). It also identifies the message as being of type VXU. The VXU is an Unsolicited Vaccination Record Update, which is one of the message types defined by HL7.
- The Patient Identification segment (**PID**) gives the client's name (MARY T SMITH), birth date (19951212, in YYYYMMDD format), and other identifying fields.
- The Common Order segment (ORC) tells that the filter order number is 1, the unique identifier from sending system DCS.
- The Pharmacy Administration segment (**RXA**) tells that a DTP vaccine, with CVX code 01, was administered on September 3, 1997 (formatted as 19970903). Many fields are optional and this example may have more information included in it. Some segments can be repeated within a single message. In this example, the message could have included a second RXA segment to record another immunization given.

Note*: While not all immunization messages are able to be associated with an order, each RXA must be associated with one ORC, based on HL7 2.5.1 standard.

HL7 does not specify how messages are transmitted. It is flexible enough to be used for both real-time interaction and large batches. The standard defines file header and file trailer segments that are used when a number of messages are gathered into a batch for transmission as a file. NESIIS will provide a response according to the type of file initially submitted via data exchange. If data was batched, the NESIIS response will be a batch. Likewise, if the data submitted was a single record, NESIIS will respond to that single record.

Scope of this Document

The General Transfer Specification (GTS) documented here supports automated exchange of data between the NESIIS repository and outside systems. This allows both the client and immunization records to be available in both systems, so as to avoid the need to enter data twice. The remainder of this document specifies how HL7 file messages are constructed for the purposes of NESIIS. It does not cover the methods that are used to transmit files between the NESIIS central repository and outside systems. It covers only a small subset of the very extensive HL7 standard. Files of messages constructed from the guidelines in this document will fall within the HL7 standard, but there are a wide variety of other possible HL7 messages that are outside the scope of this document.

References

- See Version 2.5.1 of the Health Level 7 standard for a full description of all messages, segments, and fields. Information regarding HL7 is at www.hl7.org.
- The National Immunization Program within the Center for Disease Control (www.cdc.gov/nip) has published an Implementation Guide for Immunization Data with the purpose of keeping the use of HL7 for immunization data as uniform as possible. NESIIS follows the HL7 message set by adhering to the CDC's National Immunization Program's Release 1.5 HL7 Version 2.5.1 Implementation Guide for Immunization Messaging.

HL7 Message Types used in NESIIS Transmissions

NESIIS uses these message types: VXU, ACK, QBP and RSP.

The VXU is used for sending client data and immunizations.

The ACK is used to acknowledge to the sender that a message has been received.

The QBP is used to query for a client's demographic, immunization and recommendation information (recommendations according to the ACIP schedule).

The RSP is used to response QBP messages.

The tables below show the segments that are used to construct each message type. Each segment is one line of text ending with the carriage return character. The carriage return is needed so that the HL7 messages are readable and printable. The messages may appear somewhat cryptic due to the scarcity of white space. (The standard has provisions for inclusion of binary data, but NESIIS will not use these features.) Square brackets [] enclose optional segments and curly braces {} enclose segments that can be repeated. Any number of NK1 segments could be included in the message. The full HL7 standard allows additional segments within these message types, but they are unused by NESIIS. In order to remain compliant with HL7, their use will not result in an error, but the recipient can ignore the content of the message. The segments that are documented here are sufficient to support the principal NESIIS functions of storing data about clients and immunizations.

VXU

Unsolicited Vaccination Record Update

MSH Message Header PID Patient Identification

[PD1] Patient Additional Demographic [{NK1}] Next of Kin / Associated Parties {ORC Common Order Segment

RXA Pharmacy / Treatment Administration

[RXR] Pharmacy / Treatment Route (Only one RXR per RXA segment)

[{OBX}]] Observation/Result*

ACK

General Acknowledgment
MSH Message Header

MSA Message Acknowledgment

[{ERR}] Error Segment

RECOMMENDATIONS:

The ADT is used for sending out client data without any immunizations. NESIIS will NOT accept an ADT message (unsolicited demographic update) for a new client. Therefore, it is best to include the demographic information in a VXU message whenever possible, as this message type accommodates BOTH immunization information and demographic update information. As an ADT message can be received as an outbound file, when a query is received for a client with no immunization information, below is the table of segments for an ADT message:

ADT

Update Patient Information
MSH Message Header
PID Patient Identification

[PD1] Patient Additional Demographic [NK1] Next of Kin / Associated Parties

[{*OBX}] Observation/Result

*The only OBX segment that is valid within an ADT message is one that specifies a CONTRAINDICATION in the OBX-03 Value Type field. (i.e., 30945-0^Contraindication^LN)

When a VXU^V04^VXU_V04 (Unsolicited Vaccination Record Update) message type is sent with no valid RXA segment, the client will be rejected per current business rules.

When a VXU^V04^VXU_V04 (Unsolicited Vaccination Record Update) message type is sent with no ORC associated to a RXA segment, then the client will be rejected. Similarly, an ORC segment with no associated RXA segment will result in message rejection.

QBP

Query by Parameter

MSH Message Header

QPD Query Parameter Definition Segment RCP Response Control Parameter

record includes demographic and immunization information.

*Organizations send the Query by Parameter (QBP) message to request a patient's complete immunization history. The patient

RSP

Response

MSH Message Header

MSA Message Acknowledgment Segment

[ERR] Error

QAK Query Acknowledgment Segment QPD Query Parameter Definition Segment

PID Patient Identification

PD1 Patient Additional Demographic {NK1} Next of Kin / Associated Parties {ORC Common Order Segment

RXA Pharmacy / Immunization administration

[RXR] Pharmacy / Treatment Route

[{OBX}]} Observation / Result

Note:

In real-time processing, NESIIS returns only one file. This response file contains the RSP message with the corresponding query, demographic and /or immunization information.

In batch file processing, NESIIS sends two files: a response file and an outbound file. This response file only contains the query information in RSP message form. A separate outbound file relays the demographics and/or immunization history.

The RSP segments returned depend on how many NESIIS records meet the search criteria.

NESIIS finds one patient - When NESIIS finds only one patient that matches the search, the RSP message displays
the requested patient's demographic and immunization information. This response can display all segments listed
under RSP Response message.

Note:

When available and when a single client is found, NESIIS returns the SR State Registry Identifier and the PI Patient Internal Identifier (entered as any chart number) in the PID-3 Patient Identifier List field.

• **NESIIS finds multiple patients** - When NESIIS finds multiple patients that match the request, the RSP message displays only demographic information for each possible match. This allows the organization to choose the correct

^{*}NESIIS responds to QBP messages with a file that contains a Response (RSP) message.

patient based on information like the patient's sex or address. This response can display MSH, MSA, QAK, QPD, PID, PD1, and NK1 segments.

Note:

When NESIIS finds **Z31** multiple candidates for an RSP Response message to a QBP Query, NESIIS returns each patient's demographics. The requesting person must review each candidate until he/she finds the desired patient. The person then sends another QBP with the additional demographic information found during review. NESIIS should now send a **Z32** response for one patient, which includes the complete immunization history.

- **NESIIS does not find the patients** When NESIIS does not have the patient's record, the RSP message shows that NESIIS did not find the record. The Response message displays NF for Not Found in field QAK-2 Query Response Status. This response can display only MSH, MSA, QAK, and QPD segments.
- NESIIS finds too many patients When NESIIS finds more patients the organization lists in RCP-2 Quantity Limited
 Request, the RSP message shows that NESIIS found too many records. The Response message displays TM for Too
 Many Candidates in field QAK-2 Query Response Status. This response can display only MSH, MSA, QAK, and QPD
 segments. We suggest organizations modifying the query provide more information, such as client's sex, address or
 mother's maiden name etc.

Message Segments: Field Specifications and Usage

HL7 Segment Structure

Each segment consists of several fields that are separated by "|", which is the field separator character. The tables below define how each segment is structured and contain the following columns:

1.	SEQ	The ordinal position of the field in the segment. Since NESIIS does not use all possible fields
		in the HL7 standard, these are not always consecutive.
2.	LEN	Maximum length of the field
3.	DT	HL7 data type of the field. See below for definition of HL7 data types.
4.	R/M	R means required by HL7, and M means mandatory for NESIIS. Blank indicates a required
		but may be empty field. CE means conditional but may be empty.
5.	RP/#	Y means the field may be repeated any number of times, an integer gives the maximum
		number of repetitions, and a blank means no repetition is permitted.
6.	TBL#	Number of the table giving valid values for the field.
7.	ELEMENT NAME	HL7 name for the field.

- **HL7 data types.** Each field has an HL7 data type. Appendix A of this document lists and defines the HL7 data types needed for NESIIS. The elemental data types Numeric (NM) and String (ST) consist of one value, while some data types, such as Extended Person Name (XPN) are composites.
- **Delimiter characters.** Field values of composite data types consist of several components separated by the **component separator**, "^". When components are further divided into sub-components, these are separated by the **sub-component separator**, "&". Some fields are defined to permit repetition separated by the **repetition character**, "~". When these special characters need to be included within text data, their special interpretations are prevented by preceding them with the **escape character**, "\".

```
MSH|^~\&| .....
XXX|field1|component1^component2^subcomponent3.1&subcomponent3.2^component4| .....
YYY|repetition1~repetition2| .....
ZZZ|data includes escaped \\~ special characters| .....
```

In the example above, the Message Header segment uses the field separator, "|", immediately after the "MSH" code that identifies the segment. This establishes what character serves as the field separator throughout the message. The next field, the four characters "^~\&", establishes, in order, the component separator character, the repetition character, the escape character, and the sub-component separator character that will apply throughout the message. The hypothetical "XXX" segment includes field1 with no internal structure, but the next field has several components separated by "^", and the third of these is made up of two sub-components separated by "&". The hypothetical "YYY" segment's first field permits repetition, in this example the two values "repetition1" and "repetition2". The hypothetical "ZZZ" segment's field has a text value that includes the characters "|~", and these are escaped to prevent their normal structural interpretation.

In NESIIS, sub-components, repetition and text values requiring the escape character will be rare. Components within fields are common, since names and addresses are represented this way. HL7 permits the use of other delimiters besides the

recommended ones and the delimiters used in each message are given in the Message Header segment. NESIIS will always use the recommended delimiters when sending files and requires their use for files received.

Rules for Sending Systems

The following rules are used by sending systems to construct HL7 messages.

- Encode each segment in the order specified in the message format.
- Begin the segment with the 3-letter segment ID (for example RXA).
- Precede each field with the data field separator ("|").
- Use HL7 recommended encoding characters ("^~\&").
- Encode the data fields in the order given in the table defining segment structure.
- Encode the data field according to its HL7 data type format.
- Do not include any characters for fields not present in the segment. Since later fields in the segment are encoded by ordinal position, fields that are not present do not reduce the number of field separators in the segment. For example, when the second and third fields are not present, the field separators maintain the ordinal position of the fourth field: |field1||field4
- Data fields that are present but explicitly null are represented by empty double quotes "".
- Trailing separators may optionally be omitted. For example, |field1|field2||||| is equivalent to |field1|field2, when field3 and subsequent fields are not present.
- End each segment with the segment terminator (<u>always</u> the carriage return character, ASCII hex 0D).

The following rules are used by receiving systems to process HL7 messages.

- Treat data segments that are expected but not present as if all data fields in the segment were not present.
- Require use of HL7 recommended Field Separator |, and Encoding characters ^~\& for encoding messages.
- Ignore any data segment that is included but not expected, rather than treating it as an error. The HL7 message types used by NESIIS may include many segments besides the ones in this document, and NESIIS ignores them. NESIIS will not send messages with segments not documented in this specification, but reserves the right to specify more segments at a later date. The rule to ignore unexpected segments facilitates this kind of change.
- Ignore data fields found but not expected within a segment.

The message segments below are needed to construct message types that are used by NESIIS. Each segment is given a brief description excerpted from the HL7 standard. The tables define what fields make up each segment. Since NESIIS does not use all the fields that HL7 defines, there are sometimes gaps in the ordinal sequence of fields. Following HL7 rules, the gaps do not diminish the number of field separators within the segment. For example, if the second and third fields in a segment are not present, their field separators remain in order to indicate that the next field present is the fourth: field1|||field4.

MSH

The MSH segment defines the intent, source, destination and some specifics of the syntax of a message.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	1	ST	R			Field Separator
2	4	ST	R			Encoding Characters
3	180	HD	RE			Sending Application
4	180	HD	R			Sending Facility
5	180	HD	RE			Receiving Application
6	180	HD	RE			Receiving Facility
7	26	TS	R			Date/Time Of Message
9	7	CM	R			Message Type
10	20	ST	R			Message Control ID
11	3	PT	R		0103	Processing ID
12	60	VID	R		0104	Version ID
15	2	ID	R		0155	Accept Acknowledgment Type
16	2	ID	R		0155	Application Acknowledgment Type
21	427	El	RE			Message Profile Identifier
22	180	XON	RE			Sending Responsible Organization
23	180	XON	RE			Receiving Responsible Organization

Field Notes:

- MSH-1 Determines the field separator in effect for the rest of this message. NESIIS requires the HL7 recommended field separator of "|".
- MSH-2 Determines the component separator, repetition separator, escape character, and sub-component separator in effect for the rest of this message. NESIIS requires the HL7 recommended values of ^~\&.
- MSH-3 Name of the sending application. When sending, NESIIS will use "NESIIS" followed by the current version number of the registry. See MSH-4 and MSH-6 for the fields principally used to identify sender and receiver of the message.
- MSH-4 Required by NESIIS. Segment identifies for whom the message is being sent (the owner of the message information). When sending, NESIIS will use "NESIIS". When the message is being sent to NESIIS and the Provider Organization owning the information is different than the organization transmitting the message, use either the NESIIS Provider ID of the Provider Organization that owns the information preceded by a component separator (e.g., ^36) or the short Provider Organization name (e.g., IRPH.) This value is required for inventory deduction via data exchange.
- MSH-5 Identifies the receiving application. Acceptable values for this field are "NESIIS" and <empty>. If a value other than "NESIIS" is submitted, discard and store <empty> value in database.
- MSH-6 Identifies the organization responsible for the operations of the receiving application. Acceptable values for this field are "NDHHS," "NESIIS," and <empty>. If value other than "NDHHS" or "NESIIS" is submitted, discard and store <empty> value in database.
- MSH-7 Date and time the message was created. NESIIS ignores any time component. See the TS data type.
- MSH-9 This is a required field. Three components of this field give the HL7 message type (see Table 0076) and the HL7 triggering event (see Table 0003) and the HL7 Message Structure (HL7 Table 0354). Within HL7, the triggering event is considered to be the real-world circumstance causing the message to be sent. For NESIIS purposes, this field should have the following values; VXU^V04^VXU_V04 for VXU messages, and QBP^Q11^QBP_Q11 for QBP messages. In acknowledgement messages the value ACK is sufficient and the second component may be omitted.
- MSH-10 This is a required field. Message rejection will result if nothing is received in this field. The message control ID is a string (which may be a number) uniquely identifying the message among all those ever sent by the sending system. It is assigned by the sending system and echoed back in the ACK message sent in response.
- MSH-11 The processing ID to be used by NESIIS is **P** for production processing. If any value other than P is submitted, an error message is generated indicating that NESIIS is defaulting to **P**. If this field is blank, the record is rejected and an error message is generated.
- MSH-12 This is a required field. For the parser, the version number that is read in the first MSH segment, of the file, will be the version assumed for the whole file. For example, use a value of "2.3.1" to indicate HL7 Version 2.3.1, "2.4" to indicate HL7 Version 2.4, or "2.5.1" to indicate HL7 Version 2.5.1. Messages conforming to the specifications in this Guide shall indicate that the version is 2.5.1. If there is no version number found in the first MSH segment, a hard error will occur and the file will not be processed.

 **For NESIIS to PO providers, the Exchange Data screen will need to be set to the version number that the organization has selected, in which to receive their data files. Setting the version number "tells" the writer which HL7 version format to use when generating the file in (the default will be the most recent version).
- MSH-15 This field identifies the conditions where a system must return accept acknowledgments to this message. Acceptable values are AL (Always), ER (Error/Reject Conditions Only), and <empty>. If value other than ER is submitted, or the field is left blank, NESIIS assigns it ER value. NESIIS ignores this value from sending organizations.
- MSH-16 Controls what type of acknowledgement (ACK) NESIIS generates for each message in the file submitted. If MSH-16 is submitted NESIIS is required to process the value and generate the appropriate message. Acceptable values are AL (Always), ER (Error/Reject Conditions Only), and <empty>. If value other than AL or ER is submitted, or the field is left blank, NESIIS assigns it AL value. If populated with a value of AL, NESIIS will return full acknowledgment of every message inside the file submitted.
 - **Note:** The value provided in MSH-16 directly impacts the ability of NESIIS to analyze messages for accuracy. While NESIIS can technically accept a value of 'NE' in MSH-16, this value does not return feedback to the sending organization **and** prohibits NESIIS from properly analyzing the message for data quality. As such, it will not be an allowed value for data exchange.
- MSH-21 Contains the profile used when responding to a query. NESIIS requires this field when the MSH-9 Message Type contains RSP^K11^RSP_K11 for an RSP message type and NESIIS finds one or more clients that match the search criteria. Message profiles contain detailed explanations of grammar, syntax, and usage for a message or message set. Acceptable values for this field are "Z34^CDCPHINVS" and "Z44^CDCPHINVS" for QBP messages, "Z22^CDCPHINVS" for VXU messages, and <empty>. If this field is left blank (inbound), NESIIS will assign the value "Z22^CDCPHINVS" in the database for VXU messages and "Z34^CDCPHINVS" for QBP messages, and return an error message.

- MSH-22 Identifies business organization that originated and is accountable for the content of message. This value, if sent, should match the value in MSH-4. If the value is different from MSH-4, NESIIS will store the value from MSH-4, and return an error message.
- MSH-23 Identifies business organization that is the intended receiver of the message and is accountable for acting on the data conveyed by the transaction. Value in this field is ignored for inbound files, should return same value as MSH-6 in outbound file.

PID

The PID segment is used by all applications as the primary means of communicating patient identification information. This segment contains permanent patient identifying and demographic information that, for the most part, is not likely to change frequently.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	4	SI	RE			Set ID - PID
3	20	CX	R	Υ	0203	Patient ID (Internal ID)
5	48	XPN	R	Υ		Patient Name
6	48	XPN_M	RE	Υ		Mother's Maiden Name
7	26	TS	R			Date/Time of Birth
8	1	IS	RE		0001	Sex
10	80	CE	RE	Υ	0005	Race
11	106	XAD	RE	Υ		Patient Address
13	40	XTN	RE			Phone number – home
19	16	ST	Х			SSN Number – Patient
22	80	CE	RE	Υ	0189	Ethnic Group
24	1	ID	RE		0136	Multiple Birth Indicator
25	2	NM	CE			Birth Order
29	26	TS	RE			Patient Death Date and Time
30	1	ID	RE		0136	Patient Death Indicator

Field Notes:

- PID-1 Set ID PID. This field contains the number that identifies the transaction. For the first occurrence of the segment, the sequence number shall be one, for the second occurrence, the sequence number shall be two, etc.
- PID-3 Sub-components 1 (ID), 4 (Assigning Authority), and 5 (identifier type code) are required in the PID-3 field. When a Provider Organization is sending to NESIIS, use the sending system's Chart Number or other identifier if available. When NESIIS is sending to an outside system it will use the client's NESIIS ID and chart number when it is available. Table 0363 contains valid values for sub-component 4, which, if left blank, will default to NEA. Table 0203 contains valid values for sub-component 5. If a valid SSN is sent in PID-3, NESIIS will accept and store this SSN value. If a valid SSN is sent in both PID-3 and PID-19, NESIIS will accept and store SSN value in PID-3. NESIIS supports repetition of this field.

Note: Social security number is used for identification purposes only, and is not displayed in screens or distributed to Provider Organizations. Support of PID-19 is for backwards compatibility only. NESIIS does not require inclusion of hyphens in the SSN. The following is an example of submitting the client's SSN in PID-3:

PID|||158465926^^^\$S^^^^^|

- PID-5 See the XPN data type. Last name and first name are required in the first two components. If the Name Type Code component is included, use L-Legal *NOTE: If client does not have a first name*, NO FIRST NAME *must be entered*. NESIIS does not support repetition of this field.
- PID-6 See the XPN_M data type. In this context, where the mother's name is used for client identification, NESIIS uses only last name and first name. A mother's legal name might also appear in the context of an NK1 segment. NESIIS does not support repetition of this field.
- PID-7 Give the year, month, and day of birth (YYYYMMDD). NESIIS ignores any time component.
- PID-8 See Table 0001. Use F, M, or U.
- PID-10 See Table 0005. NESIIS stores and writes "Unknown" values as null. NESIIS does not accept Hispanic or Latino as a race option. Submit it in the Ethnic Group PID-22. NESIIS does not support repetition of this field.
- PID-11 See the XAD data type. NESIIS does not support repetition of this field. Send the patient's primary address and county of residence in this field. NESIIS will also attempt to populate city, county, and state if a Nebraska ZIP Code is sent. See User Table 0289 for a list of counties.

- PID-13 See the XTN data type. Version 2.4 includes the support of the N, X, B and C sequences. NESIIS does not support repetition of this field. If PRN is specified in component 2 (telecommunication use code (ID) from table 0201)

 NESIIS will use the 6th 7th 8th and 9th components for specification of area code, phone number, extension and text, respectively. Otherwise, NESIIS will assume that the phone number is specified in the first component in the [NNN] [(999)]999-9999[X99999][B99999][C any text] format
- PID-19 NOTE: Social security number is now collected in PID-3 segment.
- PID-22 See Table 0189. NESIIS stores and writes "Unknown" values as null. NESIIS supports repetition of this field.
- PID-24 Use Y to indicate that the client was born in a multiple birth event (twins, triplets, etc.).
- PID-25 Relevant when client was born in a multiple birth event (twins, triplets, etc.). Use 1 for the first born, 2 for the second, etc. This field is useful in matching client data to existing records.
- PID-29 The date of death, if client is deceased. Give the year, month, and day (YYYYMMDD). NESIIS ignores any time component. If a death date is sent, then the Patient Registry Status in PD1-16 must indicate a value of "P" for permanently inactive/deceased.
- PID-30 Patient Death Indicator. Indicates whether the patient is deceased. Refer to HL7 Table 0136 Yes/No Indicator for valid values.

Y – the patient is deceased

N – the patient is not deceased

Empty – status is undetermined.

If Y is submitted in PID-30 field, PID-29 field is required.

PD1

The PD1 carries patient additional demographic information that is likely to change.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
11	80	CE	RE		0215	Publicity Code
12	1	ID	RE		0136	Protection Indicator
13	8	DT	CE			Protection Indicator effective date
16	1	IS	RE		0441	Immunization registry status
17	8	DT	CE			Immunization registry status effective date
18	8	DT	CE			Publicity Code effective date

Field Notes:

- PD1-11 Controls whether recall/reminder notices are sent. NESIIS will recognize "01" to indicate no recall/reminder notices or "02" recall/reminder notices any method. If values 03, 04, 05, 06, 07 are submitted NESIIS will treat them as 02. If values 08, 09, 10, 11, 12 are submitted, NESIIS will treat them as 01. NESIIS should send actual values in database via outbound DX, so that future interstate DX partners supporting those values have accurate information to work with.
- PD1-12 Controls visibility of records to other organizations. Indicates whether or not consent has been given (or assumed) for record sharing.
 - Y Protect access to data. Do not allow sharing of information data.
 - $N-\mbox{Do}$ not protect access to the data. Allow sharing of immunization data.

<empty>

Null or other values in this field will default to a value of 'N'.

Note: Nebraska is an opt-out state. By default this segment, if submitted, would be populated with a value of 'N'. Y will store as unknown.

- PD1-13 Effective date for protection indicator reported in PD1-12. Format is YYYYMMDD.
- PD1-16 Identifies the registry status of the patient. See table 0441. If a code of P is specified, the PID-29 segment must be filled in with Client Death Date or record will be rejected. If a code of P is specified, the PID-30 segment defaults to Y, and client death indicator is set to Y.
- PD1-17 Effective date for registry status reported in PD1-16. Format is YYYYMMDD. If PD1-16 Immunization Registry status exists, an organization must value this field.
- PD1-18 Effective date for publicity code reported in PD1-11. Format is YYYYMMDD. If PD1-11 Publicity Code exists, an organization must value this field.

NK1

The NK1 segment contains information about the patient's other related parties. Any associated parties may be identified. Utilizing *NK1-1-set ID*, multiple NK1 segments can be sent to patient accounts.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	4	SI	R			Set ID - NK1
2	48	XPN	R		0200	Name
3	60	CE	R		0063	Relationship
4	106	XAD	RE		0190	Address
5	40	XTN	RE			Phone Number

Field Notes:

- NK1-1 This field contains the number that identifies the transaction. Sequential numbers. Use "1" for the first NK1 within the message, "2" for the second, and so forth (default to 1 if left blank). Although this field is required by HL7, NESIIS will ignore its value, and there is no requirement that the record for the same responsible person keep the same sequence number across multiple messages, in the case that information from the same record is transmitted more than once.
- NK1-2 Name of the responsible person who cares for the client. See the XPN data type. NESIIS does not support repetition of this field. Refer to HL7 Table 200 Name Type for valid values.
- NK1-3 Relationship of the responsible person to the client. See data type CE and Table 0063 in the HL7 tables. Use the first three components of the CE data type, for example |MTH^Mother^HL70063|.
- NK1-4 Responsible person's mailing address. See the XAD data type. NESIIS does not support repetition of this field. Refer to HL7 Table 190 Address type for valid values. Note: **The patient's primary address should be sent in PID-11.**
- NK1-5 Responsible person's phone number. NESIIS does not support repetition of this field. Refer to HL7 Table 0201 Telecommunication Use Code, and HL7 Table 0202 Telecommunication Equipment Type for valid values. If PRN is specified in component 2 (telecommunication use code (ID) from table 0201) NESIIS will use the 6th 7th 8th and 9th components for specification of area code, phone number, extension and text, respectively. Otherwise, NESIIS will assume that the phone number is specified in the first component in the [NNN] [(999)]999-9999[X99999][B999999][C any text] format. The patient's primary phone number should be sent in PID-13.

PV1

The PV1 segment is used to send visit-specific information.

The primary use in immunization messages in previous releases was to carry information about the client's eligibility status. This is now recorded at the immunization event (dose administered) level. Use of this segment for the purpose of reporting client eligibility for a funding program at the visit level is not supported for HL7 2.5.1.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
2	1	IS	R		0004	Patient Class
20	50	FC	М	Υ	0064	Financial Class

Field Notes:

PV1-2 See table 0004. NESIIS will store and write a value of "R" (recurring patient) for this field.

PV1-20 See table 0064. This field has been replaced with OBX-5 in HL7 2.5.1.

ORC

The Order Request Segment.

This segment is a new segment for NESIIS HL7 2.5.1 and needs to be included if submitting to NESIIS using version HL7 2.5.1 to record who entered the information, who ordered the shot and what facility ordered the shot.

Note: The "ordering" mentioned here is not related to ordering for inventory but ordering for person specific administration. Each RXA segment **must** be associated with one ORC, based on HL7 2.5.1 standard.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	2	ΙE	R			Order Control
2		El	RE			Placer Order Number
3		El	R			Filler Order Number
10		XCN	RE			Entered By
12		XCN	RE			Ordering Provider
17		CE	RE			Entering Organization

Field Notes:

- ORC-1 Order Control. Determines the function of the order segment. The value for VXU and RSP shall be RE.
- ORC-2 Placer Order Number. The Placer Order Number is used to uniquely identify this order among all orders sent by a provider organization.
 - ORC-2 is a system identifier assigned by the placer software application. The Placer Order Number and the Filler Order number are essentially foreign keys exchanged between applications for uniquely identifying orders and the associated results across applications. The sending system may leave this field empty.
- ORC-3 Filler Order Number. The Filler Order Number is used to identify uniquely this order among all orders sent by a provider organization that filled the order.
 - This field shall hold a sending system's unique immunization ID.
 - In the case where a historic immunization is being recorded, the sending system SHALL assign an identifier as if it were an immunization administered by a provider associated with the provider organization owning the sending system.
 - In the case where an RXA is conveying information about an immunization that was not given (e.g. refusal) the Filler Order Number shall be 9999.
- ORC-10 Entered By. This identifies the individual that entered this particular order. It may be used in conjunction with an RXA to indicate who recorded a particular immunization.
- ORC-12 Ordering Provider. This field contains the identity of the person who is responsible for creating the request (i.e., ordering physician). In the case where this segment is associated with a historic immunization record and the ordering provider is not known, then this field should not be populated.
- ORC-17 Entering Organization. This is the provider organization that entered this record/order. This field identifies the organization that the enterer belonged to at the time he/she enters/maintains the order, such as medical group or department. The person who entered the request is defined in ORC-10 (entered by). This value will only be stored by NESIIS is segment ORC-10 is populated.

RXA

The RXA carries pharmacy administration data. It is a child of an ORC segment, which is a repeating segment in the RSP and VXU messages. ORC is allowed to repeat an unlimited numbers of vaccinations in a message. Each RXA must be preceded by an ORC.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	4	NM	R			Give Sub-ID Counter
2	4	NM	R			Administration Sub-ID Counter
3	26	TS	R			Date/Time Start of Administration
4	26	TS	0			Date/Time End of Administration
5	100	CE	R			Administered Code
6	20	NM	R			Administered Amount
7		CE	CE			Administered Units
9	200	CE	C(R/O)	Υ	NIP001	Administration Notes
10	200	XCN	C(RE/O)			Administering Provider
11	200	LA2	C(RE/O)			Administered-at location
15	20	ST	C(R/O)	Υ		Substance Lot Number
16	26	TS	RE			Substance Expiration Date
17	60	CE	C(R/O)		0227	Substance Manufacturer Name
18	200	CE	C(R/X)		NIP002	Substance Refusal Reason
20	2	ID	RE		0322	Completion Status
21	2	ID	C(R/O)		0323	Action code - RXA

Field Notes:

RXA-1 Required by HL7. Use "0" for NESIIS.

RXA-2 Required by HL7. For PO-NESIIS loads, Data Exchange expects an incoming value of 1 for this field in HL7 2.5.1. However, if the user's system is not configured to send series information, they should use the value "999."

Note: This rule does not apply to refusals; please refer to RXA-18 for more information.

- RXA-3 Date the vaccine was given. NESIIS ignores any time component.
- RXA-4 Required by HL7. Ignored by NESIIS, which will use the value in RXA-3. If submitted, value must match the value submitted in RXA-3.
- RXA-5 This field identifies the medical substance administered. If the substance administered is a vaccine, NESIIS prefers National Drug Code (NDC) codes or CVX codes, although other coding systems are accepted (CPT-4 code, Vaccine Trade Name, or Vaccine Group Code) for the vaccine administered. NDC code is required for organizations deducting from inventory via data exchange. If submitting one data element for the vaccine administered, place the code itself in the first component of the triplet, description in the second component of the triplet and coding system in the third component of the triplet. Here's an example of a single CVX code submission for an administered vaccine, |20^DTaP^CVX^^^|. If submitting more than one data element for the vaccine administered, use triplet components four through six. For example, if NDC code was submitted in addition to CVX code, use the fourth component of the triplet for the code itself, fifth component of the triplet for description and "NDC" in the sixth component of the triplet, |20^DTaP^CVX^58160-0810-43^10 pack-1 dose vials^NDC|. (NOTE: Use hyphens when reporting NDC code). If using CPT code, use "CPT" as the name of the coding system. See the CE data type and HL7 Table 0292 (CVX Codes), and NESIIS Table WCPT (CPT Codes).

The following is an example of the correct formatting for the RXA-5 segment:

RXA|0|1|20050919|20050919|10^IPOL^CVX^49281-0860-10^10 dose vial^NDC

- RXA-6 Administered Amount. This field records the amount of pharmaceutical administered. The units are expressed in the next field, RXA-7. When the administered amount is unknown, this field should record the value "999."
- RXA-7 Administered Units. This field is conditional because it is required if the administered amount code does not imply units. This field must be in simple units that reflect the actual quantity of the substance administered. It does not include compound units. This field is not required if the previous field (RXA-6) is populated with "999." For specific Vaccine Trade Names, Dosage Type may indicate the unit type for an administered vaccine. For example, mL, MCG, IU or CAPS. (See New Deduct From Inventory section)
- RXA-9 NESIIS will recognize 00 to indicate a new administered vaccine or 01 to indicate Historical Record. When sending, NESIIS will include the corresponding immunization ID in the second repeating segment. This field is required if RXA-20 is valued "CP" or "PA." Note: Historical Record vaccines will not apply an inventory deduction for the vaccine lot.

|01^historical^NIP001|

Note: If this field is left blank, the immunization will be recorded as historical in NESIIS.

RXA-10 Administering Provider. This field is intended to contain the name and provider ID of the person physically administering the pharmaceutical. This field is required if the first occurrence of RXA-9.1 is valued "00," and RXA-20 is valued "CP" or "PA." NESIIS will return the Administering Provider only if the submitted data is appropriately formatted and is owned by the provider requesting the data.

|^SMITH^SALLY^S^^^^^^VEI|

Note: In HL7 2.5.1, the ordering and entering providers are indicated in the associated ORC segment.

- RXA-11 The name and address of the facility that administered the immunization. Place the facility name in component 4. This field is required if the first occurrence of RXA-9.1 is valued "00," and RXA-20 is valued "CP" or "PA."
- RXA-15 This field contains the manufacturer's lot number for the vaccine. It may remain empty if the dose is from a historical record. This field is required if the first occurrence of RXA-9.1 is valued "00," and RXA-20 is valued "CP" or "PA." NESIIS does not support repetition of this field.
- RXA-16 This field contains the expiration date of the medical substance administered. It may remain empty if the dose is from a historical record. Date the vaccine expires in YYYYMMDD format. When only the year and month are populated, NESIIS will populate the day as the last day of the month. NESIIS ignores any time component. This field is required if the first occurrence of RXA-9.1 is valued "00," and RXA-20 is valued "CP" or "PA."
- RXA-17 Vaccine manufacturer from Table 0227, for example |AB^Abbott^ MVX^^^|. For vaccines, code system MVX should be used to code this field, not HL70227. NESIIS does not support repetition of this field. This field is required if the first occurrence of RXA-9.1 is valued "00," and RXA-20 is valued "CP" or "PA."
- RXA-18 When applicable, this field records the reason the patient refused the vaccine. See table NIP002. Any entry in this field indicates that the patient did not take the substance. IF this field is populated, RXA-20 (Completion Status) shall

be populated with RE. The vaccine that was offered should be recorded in RXA-5. Do not record contraindications, immunities or reactions in this field. NESIIS does not support repetition of this field.

Notes on Refusals:

- a) NESIIS only stores the fact that a refusal of a vaccine occurred, not a specific type of refusal, so all outgoing refusals will be designated as "PARENTAL REFUSAL." Please see the example below.
- b) The NESIIS system will not write out refusals which do not have an "Applies-to" date. It will write out multiple refusals for the same vaccine on different dates for those clients who have them.
- c) The NESIIS system will accept incoming refusals of the same vaccine on different dates and file them both. However, if they both have the same applies-to date, then only one will be stored.
- d) The sending organization will become the refusal owner. In general, only the organization who owns the refusal is permitted to edit it. However, in the case of parent and child organizations, the parent may edit the child's refusals and vice versa.

Here is a sample RXA segment for an MMR refusal given on the date 01/01/2007: RXA|0|0|20070101|20070101|00006-4681-00^10 pack-1 dose vials^NDC |1.0|||||||||00^PARENTAL REFUSAL^NIP002^^^||RE|

RXA-20 For Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7, this field indicates if the dose was successfully given. It must be populated with value RE if RXA-18 is populated. Partially administered dose is represented by the value PA. A partially administered dose refers to the scenario where the patient jumps and the needle dislodged resulting in an unknown quantity of vaccine entering the patient's system.

RXA-21 Action Code.

This field indicates the action expected by the sending system. Allows an organization to add to or delete records. If it is left empty, then NESIIS default to "A" for additions. To delete an existing immunization in NESIIS, specify a value of "D". The immunization can only be deleted if it is owned by the same organization requesting the delete. No more than 5% of all incoming immunizations in a batch load file can be flagged as delete requests. The total number of delete requests in a single file cannot exceed 50 total.

Note: For updates and additions, organizations shall use "A" additions in RXA-21, NESIIS determines whether to update the record or add a new immunization.

Here is a sample RXA segment for an update and additional immunization:

RXA|0|1|20050919|20050919|10^IPOL^CVX^49281-0860-10^10 dose vial^NDC |1.0||01^Historical^^^^^^||||||||||A|

RXR

The Pharmacy/Treatment Route Segment contains the alternative combination of route and site.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	60	CE	RE		0162	Route
2	60	CE	RE		0163	Site

Field Notes:

RXR-1 This is the route of administration from HL7 table 0162 or NCIT code.

RXR-2 This is the site of the route of administration from table 0163.

OBX

The Observation/Result Segment is used to transmit an observation.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1	4	SI	R			Set ID-OBX
2	3	ID	R			Value type
3	80	CE	R			Observation Identifier
4	20	ST	R			Observation sub-ID
5	65536	-	R			Observation Value
11	1	ID	R		0085	Observation Result Status
14	26	TS_NZ	RE			Date/Time of the observation
17		CE	CE			Observation Method

Field Notes:

OBX-1 Sequential numbers. Use "1" for the first OBX within the message, "2" for the second, and so forth.

- OBX-2 This field contains the data type which defines the format of the observation value in OBX-5. For incoming PO-NESIIS data, Data Exchange accepts CE for Coded Entry. However, for NESIIS-PO, the system will send out values of CE, TS, NM for Coded Entry, Timestamp, and Number respectively, depending on what is actually sent in OBX-5.
- OBX-3 This field contains the observation's unique identifier. Organizations send Logical Identifier Name and LOINC Codes. The Name of Coding System in the third component must be LN for LOINC, First component and second component must report the following:
 - **30945-0 Vaccination Contraindication/Precaution**, use 30945-0 in this field and enter a Contraindication or Precaution (NIP004) in OBX-5.

Example: OBX|1|CE|30945-0^Contraindication^LN||21^acute illness^NIP^^^||||||F|| $E_{\rm NIP}^{\rm NIP}^{\rm$

- 31044-1 Reaction to Immunization, use 31044-1 in this field and enter a Reaction code (NESIIS001) in OBX-5. Example: OBX|1|CE|31044-1^Reaction^LN||HYPOTON^hypotonic^NESIIS^^^||||||F|
- **30948-4 Vaccination Adverse Event Outcome**, use 30948-4 in this field and enter an Event Consequence code (NIP005) in OBX-5.

Example: OBX|1|CE|30948-4^Adverse Outcome^LN|E^er room^NIP^^^||||||F

• **64994-7 VFC Eligibility to Immunization**, use 64994-7 in this field and enter a VFC Eligibility code (from the HL7 0064 table for Financial Class) in OBX-5.

Note: If using a Nebraska-specific code (NE01-04), use NESIIS in OBX-5.3.

Example:

RXA|0|999|20061017|20061017|51^HepB-Hib^CVX^^^|0|||00^^^^||||||||||||

OBX|1|CE|64994-7^Vaccine Elig Code^LN^^^||V05^Underinsured^HL70064||||||F|

OBX|1|CE|64994-7^Vaccine Elig Code^LN^^^||NE03^Not VFC Eligible – Uninsured (Adult)^NESIIS|||||||F|

• **30963-3 Vaccine Funding Source to Immunization**, use 30963-3 in this field and enter a Vaccine Funding Source code (from the NIP008 table) in OBX-5.

Example:

RXA/0/999/20061017/20061017/51^HepB-Hib^CVX^^^/0///00^^^^///////////////////////

OBX|1|CE|30963-3^Vaccine purchased with^LN^^^|PBF^Public Funds^NIP008||||||F|

• **59784-9 Disease with presumed immunity** and **75505-8 Serological Evidence of Immunity**, use 59784-9 or 75505-8 in this field, and enter an Evidence of Immunity Code (from the HL70396 table) in OBX-5.

Evidence of immunity indicates that a person has plausible evidence that they have already developed immunity to a particular disease. The strongest evidence of immunity is when serological evidence indicates immunity. An alternative evidence of immunity is when a clinician has determined that the patient has a history of the disease.

The example below shows that no dose of vaccine was given because the person had evidence of previous infection with Hep B.

ORC|RE||9999^DCS|||||||^Admin^Bob| <CR>

RXA|0|999|20150802|20150802|998^No vaccine administered^CVX|999|||00^^^^^^^\|||||||||||RE|A|20150910141143

OBX|1|CE|59784-9^Disease with presumed immunity^LN||66071002^HISTORY OF HEP B INFECTION^SCT^^^||||||F|||||

Note: Use CVX code 998 in RXA-5 when no vaccine is administered. Always use 998 in RXA-5 when using LOINC codes 59784-9 and 75505-8.

For Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7, the system uses this field to send the LOINC Codes for **Series information** for combination vaccines. For each component of a combination vaccine, the system sends out a grouped set of two OBX segments. The first segment identifies the component antigen, and the second segment identifies the Series count. OBX-3 is used to identify whether the component antigen or the valid series count is noted in OBX-5 respectively.

Here are the LOINC Codes that the system sends in OBX-3 for Series information for combination vaccines.

LOINC Code	Description
38890-0	Component Vaccine Type. This term is used to distinguish separate vaccine components of a multiple antigen vaccine. Included in LOINC 1/2005.
30973-2	Dose Number in Series
30956-7	Vaccine Information Statement (VIS) vaccine type
69764-9	VIS document type
29768-9	VIS version date
29769-7	VIS delivery date

In the following example, the LOINC Codes are highlighted in OBX-3. These two OBX segments together express that a dose of combination vaccine counts for the 1st dose of DTaP in the DTaP series.

```
OBX|1|CE|38890-0^COMPONENT VACCINE TYPE^LN|1|20^DTaP^CVX^90700^DTaP^CPT|||||||F|
OBX|2|NM|30973-2^Dose number in series^LN|1|1||||F|
```

Please see the end of the OBX field notes for a complete example of how NESIIS sends Series information for combination vaccines.

For Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7, the system uses this field to send the LOINC Codes for **Recommendations**. For each recommendation, the system sends a grouped set of five OBX segments. Here are the LOINC Codes that the system sends out in OBX-3 for Recommendations. The LOINC itself is sent in OBX-3 in order to identify what the value in OBX-5 represents.

LOINC Code	Description
30979-9	Vaccines Due Next
30980-7	Date Vaccine Due
30973-2	Vaccine due next dose number
30981-5	Earliest date to give
30982-3	Reason applied by forecast logic to project this vaccine

In the following example, the LOINC Codes are highlighted in OBX-3 for a single recommendation of HepB.

Please see the end of the OBX field notes for a complete example of how NESIIS sends Recommendations.

OBX-4 For sending out Series Information and Recommendations, the number in this field groups together related OBX segments. For example, a single recommendation for DTP/aP is sent in a grouped set of five OBX segments, all with the same sub-identifier in OBX-4. The sub-identifier will increment sequentially. Value constrained to positive integers only.

For example, NESIIS sends out five grouped OBX segments for each recommendation. The following is a single MMR recommendation, all sharing the same Observation sub-ID of 4 in OBX-4.

OBX-5 Text reporting Contraindication or Precaution (NIP004), Immunity (HL70396), Reaction (NESIIS001), Event Consequence (NIP005), Vaccine Funding Source (NIP008) or VFC Eligibility (HL70064). NESIIS has imposed a CE data type upon this field, the first component of which is required.

```
(e.g., |PERTCONT^Pertussis contra^NESIIS^^^|)
```

For Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7, this field holds the value observed for series information and recommendations. The value corresponds to the LOINC in OBX-3. For example, for recommendations, the fourth OBX segment is for the earliest date. OBX-3 contains the code 30979-9&30981-5 and OBX-5 contains the actual earliest date as follows:

```
OBX|4|TS|30981-5^Earliest date to give^LN^^^|1|20010519|||||F|
```

Please see the end of the OBX field notes for complete examples of how NESIIS sends Series for combination vaccines and Recommendations.

- OBX-11 Required for HL7. Use "F" for NESIIS.
- OBX-14 Records the date/time of the observation. The observation's date in YYYYMMDD format. NESIIS ignores any time component.
- **NOTE 1:** The only valid OBX Observation Identifier (OBX-03) for an **ADT^A31** message type is Contraindication/Precaution (30945-0).
- **NOTE 2:** All OBX messages with an observation identifier of Vaccination Contraindication/Precaution will be returned in an outgoing file in a separate ADT message for the client.
- **NOTE 3:** Complete Example of NESIIS's use of OBX to send Series Information for Combination Vaccines is listed below:

A single dose of combination vaccine may have a different series dose count for each component. For Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7, the system sends a grouped set of three OBX segments for each component in a combination vaccine. For example, a single dose of DTaP-Hib is sent as below. The first three OBX segments express the dose count of 1 for DTaP. The last three OBX segments express the dose count of 3 for Hib.

NOTE 4: Complete Example of NESIIS's use of OBX to send Recommendation Information is listed below:

For Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7, a single recommendation is sent in a grouped set of five OBX-segments, which follow a place-holder RXA segment that does not represent any actual immunization administered to the client. The five OBX segments in order express the Vaccine of the recommendation, the recommended date, the dose of the next vaccine due, the earliest date to give, and the reason for the recommendation, which is always the ACIP schedule.

```
RXA|0|0|20010407|20010407|998^No Vaccine Administered^CVX|999|0

OBX|1|CE|30979-9^Vaccines Due Next^LN^^^|1|20^DTP/aP^CVX^90700^DTP/aP^CPT||||||F|

OBX|2|TS|30980-7^Date Vaccine Due^LN^^^|1|20010607|||||F|
```

```
OBX|3|NM|30973-2^Vaccine due next dose number^LN^^^|1|1|||||F|
OBX|4|TS|30981-5^Earliest date to give^LN^^^|1|20010519|||||||F|
OBX|5|CE|30982-3^Reason applied by forecast logic to project this vaccine^LN^^^|1|^ACIP
schedule||||F|
OBX | 6 | CE | 30979-9 Vaccines Due Next LN ^ ^ | 2 | 85 HepA CVX ^ 90730 ^ HepA ^ CPT | | | | | | | | | |
OBX | 7 | TS | 30980-7^Date Vaccine Due^LN^^^|2 | 20030407 | | | | | | | F |
OBX|8|NM|30973-2^Vaccine due next dose number^LN^^^|2|1|||||F|
OBX|9|TS|30981-5^Earliest date to give^LN^^^|2|20020407||||||F|
OBX | 10 | CE | 30982-3^Reason applied by forecast logic to project this vaccine^LN^^^|2 | ^ACIP
schedule||||F|
OBX | 11 | CE | 30979-9^Vaccines Due Next^LN^^^| 3 | 45^HepB^CVX^90731^HepB^CPT | | | | | | | | | | |
OBX | 12 | TS | 30980-7^Date Vaccine Due^LN^^^ | 3 | 20010407 | | | | | | | | | |
OBX|13|NM|30973-2^Vaccine due next dose number^LN^^^|3|1|||||F|
OBX|14|TS|30981-5^Earliest date to give^LN^^^|3|20010407||||||F|
OBX | 15 | CE | 30982-3^Reason applied by forecast logic to project this vaccine^LN^^^|3 | ^ACIP
schedule|||||F|
```

The ability to send Recommendations in these grouped OBX segments applies to HL7 2.5.1 and it applies to Batch HL7 NESIIS-PO, Batch HL7 Bi-directional, and Real-time HL7. Some configuration is needed to send Recommendations in this way. On the Manage Data Exchange Screen, the **Send HL7 Series/Recommend** option displays, and the user must select either "Recommendations Only" or "Both" from the pick list. (This option is hidden if Flat File or HL7 PO-NESIIS is chosen.)

Note: Please reference page 29 for information regarding Deduct from Inventory functionality and its use of various OBX segments.

OBX-17 This optional field can be used to transmit the method or procedure by which an observation was obtained when the sending system wishes to distinguish among one measurement obtained by different methods and the distinction is not implicit in the test ID. Default to VXC40^vaccine level^CDCPHINVS if OBX-3.1 is 64994-7 for Eligibility Status.

NTE

The Note Segment

This segment is used for sending notes and comments.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1		SI	0			Set-ID
2		ID	0			Source of Comment
3	500	FT	R			Comment
4		CE	0			Comment Type

Field Notes:

NTE-3 *Note:* Immunizations may have multiple notes associated with them.

Deduct From Inventory

We are pleased to announce that NESIIS now has the ability to "Deduct from Inventory." This means data exchange organizations can effectively use the NESIIS Inventory Module in conjunction with their routine data exchange submissions. "Deduct from Inventory" functionality also provides the ability to send new dosage types and quantities for specific vaccine trade names.

Here's how it works:

- 1. Organizations must establish their NESIIS Inventory Module. This is a manual process that requires vaccine lot numbers to be created and saved in the User Interface. Data captured during this process includes: Trade Name, Manufacturer, NDC, Lot Number, Expiration Date, Dose Size and Funding Source.
- 2. Organizations submit their HL7 files to NESIIS using their approved submission method. NESIIS will process these files and attempt to match 'new' immunizations to your organization's existing inventory data in NESIIS. If NESIIS is able to find an exact lot number match (using lot number, administration code, and funding source or VFC funding eligibility), it will decrement the Quantity on Hand for that lot number.

Note: National Drug Code (NDC) is the required type for administration code in the RXA-5 field when deducting from inventory. In addition to NDC, RXA-5 can also include CVX, for DFI matching.

3. New Dosage Types are now accepted by NESIIS for specific Vaccine Trade Names. These new types are: MCG (Micrograms), IU (International Units) and CAPS (Capsule). These new types, and their accompanying quantities, are used in conjunction with specific Vaccine Trade Names which must be included as part of the vaccine information sent when also sending a new dosage type. The new types and quantities will be converted to the equivalent NESIIS dosage amount for the vaccine indicated and deducted from the appropriate vaccine lot. If NESIIS is unable to determine the trade name from the NDC, conversion will not occur.

Vaccine Trade Name and Dosage Type combinations accepted:

Vaccine Trade Name	Dosage Type
Recombivax Peds	MCG
Recombivax-Adult	MCG
Recombivax-Dialysis	MCG
Engerix-B Adult	MCG
Engerix-B Peds	MCG
Engerix-B Dialysis	MCG
Imovax Rabies ID	IU
Imovax Rabies IM	IU
RabAvert	IU
Adeno T4	CAPS
Adeno T7	CAPS
Adeno Virus types 4 and 7	CAPS
Vivotif	CAPS

4. If NESIIS is unable to find an exact lot number match (due to various reasons), the 'new' immunization record will be accepted and displayed in the client's immunization history. Information errors within the Response File will provide explanations of why Deduct from Inventory did not take place.

Note: Historical immunization records do not qualify for Deduct from Inventory.

Data exchange organizations are not required to use Deduct from Inventory functionality. However, we strongly
recommend that VFC organizations consider taking advantage of this feature. Accurate inventory quantities will
ensure efficient vaccine ordering through NESIIS.

Note: Deduct from Inventory will only function for an organization's default site. NESIIS will not check the inventory of an alternate site associated with an organization.

Highlight of Data Exchange Changes for Deduct from Inventory

Required HL7 fields for Deduct from Inventory functionality:

- 1. RXA-5, Administration Code. NDC is required for matching, and CVX is also accepted.
- 2. RXA-6 is a required field for valid dose size. Valid values for this field are: 0.1, 0.2, 0.25, 0.5, 0.65, 1.0, 2.0, and multiple of these values (1/2x, 2x, 3x, 4x, 5x). Alternate dosage sizes are also valid for new dosage types. Valid values for MCG (Micrograms) are: 5.0, 10.0, 20.0, 40.0, and multiples of these values (1/2x, 2x, 3x, 4x, 5x). Valid values for IU (International Units) are: 2.5 and multiples of this value (1/2x, 2x, 3x, 4x, 5x). Valid values for CAPS (Capsules) are: 1.0 and multiples of this value (1/2x, 2x, 3x, 4x, 5x).
- 3. RXA-7 is required when using alternate dosage types for specific Vaccine Trade Names. The field allows for new dosage types of: MCG (Micrograms), IU (International Units) and CAPS (Capsule).
- 4. RXA-15, Substance Lot Number. The incoming lot number is required. Note, Lot Number is NOT case sensitive.
- 5. OBX-2, Value Type. Type must be "CE."
- 6. OBX-3, Observation Identifier. To deduct, "30963-3^Vaccine purchased with^LN" must be used when reporting funding source, or "64994-7^Vaccine Elig Code^LN" when reporting VFC funding eligibility.

7. OBX-5, Observation Value. To deduct, "PVF^Private funds^NIP008" or "PBF^Public funds^NIP008" must be used when reporting funding source. When reporting VFC funding eligibility, values from HL7 table 0064 must be used.

File Interchange between NESIIS and Outside Systems

The central repository of NESIIS contains records of clients from around the state. Client and immunization records flow both ways between NESIIS and outside systems. Data, for a particular client, is transmitted by NESIIS to an outside system (Provider Organization) only if the client is identified as having a relationship with that Organization AND the relationship was created by transmitting the client's record to NESIIS. So, an exchange of information about a given client is always initiated by the outside system. There are three options for exchanging data with NESIIS:

- (1) The Provider Organization can send data to NESIIS and request that no data is returned from NESIIS.
- (2) The Provider Organization can request data from NESIIS while not providing data to NESIIS.
- (3) The Provider Organization can send data to NESIIS and NESIIS will return any updated information regarding the clients that have a relationship with that Provider Organization.

Note: client and immunization data can also be entered, queried, and modified using the NESIIS-Web interface. This provides an alternate way of identifying a client as having a relationship with a Provider Organization. The use of NESIIS-Web is not required to create a relationship between a Provider Organization and a client. The first transmission to NESIIS, for a client immunization record, will create the link that will cause NESIIS to transmit that client's record to the outside system.

HL7 messages are always part of a two-way exchange between an initiating system and a responder. Sometimes the initial message implies specific data to be sent in a response. Other times, as is the case with NESIIS client and immunization data, the principal response of the receiving system is to process the message and post whatever it contains to its own database. For these cases, HL7 provides the ACK message type, which contains no new application data, but allows the receiver to inform the initiator that the message has been received and processed successfully. If an error prevents successful processing, optional parts of the ACK message will allow this to be communicated as well.

For exchanges between NESIIS and outside systems, it is the responsibility of the outside system to initiate the transfer of the first file, containing VXU messages with client and immunization data. After processing those messages, NESIIS responds with a file of ACK messages. At the same time or soon after, NESIIS also creates another file of VXU messages, containing the full client record, to send to the Provider Organization that initiated the first transfer. It is the responsibility of that Organization as receiver to transmit back a file of ACK messages. During this second exchange, in terms used by HL7, NESIIS is the initiator and the outside system is the respondent. However, it is the receipt of the first file initiated by the outside system that causes NESIIS to initiate sending its own data file.

	Provider Organization	N	NESIIS
		Outgoing	Receiving
1.	Creates a file of client and immunization records that have changed since they were last transmitted to NESIIS.		
2.	Transmits the file to NESIIS.		
3.			Processes the file received, creates a file of ACK messages.
4.		Transmits the ACK file back to the initiator of the original file.	
5.	Processes the ACK file to confirm success of the file transmission.		
6.			munization records that have changed ed to this Provider Organization.
7.		Transmits this file to the Provider Organization.	
8.	Processes the file received, creates a file of ACK messages.		
9.	Transmits the ACK file back to NESIIS		
10.			Processes the ACK file to confirm success of the file transmission.

The 16th field, in the MSH message header segment, allows the initiator to ask that the message be acknowledged only in the case of an error and NESIIS supports this in order to minimize the number of ACK messages transmitted. In this case, the ACK file contains only error messages (an optional form of the ACK message type). The original messages, with no answering error messages, are implicitly acknowledged as successfully processed.

Examples

To illustrate how a NESIIS HL7 file is put together we will document how the fictional organization, Valley Clinic, formats client and immunization records to be transmitted to NESIIS. The following table displays the information to be transmitted and it is organized into HL7 segments and fields. For example, PID-3 refers to the third field in the Patient Identification segment.

nformation to transmit	Data value to be entered	HL7 Form
Client #1		PID segment
 Chart Number (ID on Valley Clinic's system) 	45LR999	PID-3
Social Security Number	444111222	PID-3
• Name	MILLER^GEORGE^M^JR	PID-5
 Mother's maiden name 	OLSON^MARTHA	PID-6
Birth date	19950227	PID-7
• Sex	M	PID-8
Patient's Primary Address	123 MAIN ST LINCOLIN, NE 68509 NE109 (Lancaster County, NE)	PID-11
 Patient's Primary Phone Number 	402 987 6543	PID-13
Multiple Birth Indicator	Y (client was born as part of a multiple birth)	PID-24
Birth Order	2 (second birth of a multiple birth)	PID-25
Publicity Code	02	PD1-11
Protection Indicator	Y (client records are visible by other provider organizations)	PD1-12
 Patient Registry Status 	A (client is active in the registry)	PD1-14
 Responsible Person (parent or other contact who cares for client) 		NK1 segment
• Name	MILLER^MARTHA	NK1-2
 Relationship to client 	MTH	NK1-3
• Address	123 MAIN ST LINCOLIN, NE 68509 NE109 (Lancaster County, NE)	NK1-4
• Phone	402 123 4567	NK1-5
Responsible Person		NK1 segment
• Name	MILLER^GEORGE	NK1-2
Relationship to client	FTH	NK1-3
Immunization (historical)		RXA segmen
Date administered	19990723	RXA-3
CVX Code	20	RXA-5
Dose size	0.5	RXA-6
Administration Notes	01	RXA-9
Administering Provider Organization	Valley Clinic	RXA-11.4
• Client #2		PID segment
Chart Number	23LK729	PID-3
• Name	CALIFANO^MARIA	PID-5
Mother's maiden name	DISTEFANO^ANGELICA	PID-6
Birth date	19990413	PID-7
• Sex	F	PID-8
Immunization (historical)		RXA segmen
Date administered	19990723	RXA-3
CVX Code	20	RXA-5

- 0				
Inform	ation to t		Data value to be entered	HL7 Format
	•	Dose size	0.5	RXA-6
	•	Administration Notes	01	RXA-9
	•	Administering Provider	Valley Clinic	RXA-11.4
	• Immun	Organization ization (historical)		RXA segment
		Date administered	19990723	RXA segment
	•		10 pack-1 dose vials	RXA-5
	•	Package Description NDC Code	00006-4681-00^NDC	RXA-5
	•	Dose size	0.5	RXA-6
	•	Administration Notes	0.5	RXA-9
	•	Administration Provider Administering Provider	Valley Clinic	RXA-11.4
		Organization	, units similar	
•	Client #3			PID segment
	• Chart N	Number	92HG9257	PID-3
	• Name		FISHER^JOSEPH	PID-5
	• Mother	's maiden name	LASOWSKI^MARY	PID-6
	• Birth d	ate	20080703	PID-7
	• Sex		M	PID-8
	 Immun 	ization (new)		RXA segment
	•	Date administered	20100102	RXA-3
	•	CVX Code	127	RXA-5
	•	Dose	0.25	RXA-6
	•	Administering Clinician	(Note the clinician last name will not be	RXA-10
			recorded in the example. An informational	
			error is generated as a result of a missing value in an optional field.)	
	•	Lot number	NVB23423	RXA-15
	•	Lot manufacturer	PMC^sanofi pasteur^HL70227	RXA-17
	• Eligibil		-	OBX segment
	•	Vaccine fund pgm elig cat	64994-7	OBX-3
	•	VFC Eligibility code	V01^Insured, Vaccines	OBX-5
			Covered^HL70064	
		g Source		OBX segment
	•	Vaccine purchased with	30963-3	OBX-3
	•	Vaccine Funding Source	PVF^Private Funds^NIP008	OBX-5
		ization (new)	20101205	RXA segment
	•	Date administered	20101205	RXA-3
	•	CVX Code	03	RXA-5
	•	Dose	0.5 ^Doe^Jane	RXA-6 RXA-10
	•	Administering Clinician	AD19487	RXA-10 RXA-15
	•	Lot number Lot manufacturer	MSD^MERCK^HL70227	RXA-13 RXA-17
	• Eligibil			OBX segment
	• Eligibii	Vaccine fund pgm elig cat	64994-7	OBX segment OBX-3
	•	VFC Eligibility code	V03^Uninsured^HL70064	OBX-5
		g Source		OBX segment
	• Tunam	Vaccine purchased with	30963-3	OBX-3
	•	Vaccine Funding Source	PBF^Public Funds^NIP008	OBX-5
•	Immun	ization (new - alt. dosage type)		RXA segment
	•	Date administered	20101205	RXA-3
	•	CVX Code	43	RXA-5
	•	NDC	00006-4995-00^^NDC	RXA-5
	•	Dose	10.0	RXA-6
	•	Dose Type	MCG	RXA-7
	•	Administering Clinician	^Doe^Jane	RXA-10
				-

Information to transmit	Data value to be entered	HL7 Format
Lot number	RA1234	RXA-15
Lot manufacturer	MSD^MERCK^HL70227	RXA-17
• Eligibility		OBX segment
Vaccine purchased with	64994-7	OBX-3
VFC Eligibility code	V03^Uninsured^HL70064	OBX-5
Funding Source		OBX segment
Vaccine purchased with	30963-3	OBX-3
Vaccine Funding Source	PBF^Public Funds^NIP008	OBX-5

In an HL7 message, each segment is a single text line, ending with the carriage return character. In the examples, long lines are broken artificially for display purposes and the carriage return character is denoted by <CR>.

```
MSH|^~\&|VALSYS|VALCLIN||NESIIS|19990802091524|| VXU^V04^VXU V04|00000123|P|2.5.1||||AL<CR>
PID|||45LR999^^^PI^~444111222^^^^SS||MILLER^GEORGE^M^JR|OLSON^MARTHA|19950227|M|||123 MAIN
      ST^^ LINCOLN^NE^68509^US^^^NE109||(402)987-6543|||||||||||Y|2<CR>
PD1 |||||||02^REMINDER/RECALL ANY MENTOD^HL70215|Y|A<CR>
NK1|1|MILLER^MARTHA|MTH^Mother^HL70063|123 MAIN ST^^ LINCOLN^NE^68509^US^^^NE109|(402)123-
      4567<CR>
NK1|2|MILLER^GEORGE|FTH^Father^HL70063<CR>
RXA|0|999|19990723|19990723|20^DTaP^CVX^^^|0.5|||01|^^^VALCLIN<CR>
MSH|^~\&|VALSYS|VALCLIN||NESIIS|19990802091524||VXU^V04^VXU V04|00000124|P|2.5.1||||ER<CR>
PID|||23LK729^^^PI^||CALIFANO^MARIA|DISTEFANO^ANGELICA|19980413|F<CR>
ORC|RE||2^DCS|||||||||||||R
RXA|0|999|19990723|19990723|20^DTaP^CVX^^^|0.5|||01|^^^VALCLIN<CR>
RXA|0|999|19990723|19990723|00006-4681-00^10 pack-1 dose vials^NDC|0.5|||01|^^^VALCLIN<CR>
MSH|^~\&|VALSYS|VALCLIN||NESIIS|19990802091526||VXU^V04^VXU V04|00000125|P|2.5.1||||ER<CR>
PID|||927389^^^^SR^~92HG9257^^^^PI^||FISHER^JOSEPH|LASOWSKI_MARY|20080703|M<CR>
ORC|RE||4^DCS|||||||||||||R
RXA|0|999|20100102|20100102|127^H1N1^CVX^^^|0.25|||00|^^JANE^^^^^^^^VEI^^||||NVB23423||PMC^
      sanofi pasteur^HL70227^^^|||<CR>
OBX|1|CE|64994-7^Vaccine fund pqm eliq cat^LN^^^|V01^Insured, Vaccines
      Covered^HL70064|||||F|
OBX|2|CE|30963-3^Vaccine purchased with^LN^^^||PVF^Private Funds^NIP008|||||F|
ORC|RE||5^DCS|||||||||||||R
RXA|0|999|20101205|20101205|03^MMR^CVX^^^|0.5|||00|^DOE^JANE^^^^^^^VEI^^||||AD19487||
      MSD^MERCK^HL70227||||A<CR>
OBX|1|CE|64994-7^Vaccine fund pgm elig cat^LN^^^||V03^Uninsured^HL70064|||||F|
OBX|2|CE|30963-3^Vaccine purchased with^LN^^^||PBF^Public Funds^NIP008|||||F|
RXA|0|999|20101205|12011205|43^HEPB-ADULT^CVX^00006-4995-00^^NDC|10.0|MCG||00|^DOE^JANE
      ^^^^^^^VEI^^||||RA1234||MSD^MERCK^HL70227||||A<CR>
OBX|1|CE|64994-7^Vaccine fund pgm elig cat^LN^^^||V03^Uninsured^HL70064||||||F|
OBX|2|CE|30963-3^Vaccine purchased with^LN^^^||PBF^Public Funds^NIP008||||||F|
```

Note: When a client is being introduced to NESIIS, the VXU message is recommended, since NESIIS must have at least one immunization for a client before being added to the database. In the example above, Valley Clinic sends a file of three HL7 messages to NESIIS.

Client George M Miller Jr. is identified by Valley Clinic's chart number, 45LR99 and SSN 444111222, in his PID segment. The message could have included George's NESIIS ID number in field PID-3, but does not have to, if it is not recorded in Valley Clinic's system. George's mother's maiden name, his birth date, gender and address, also serve to identify him. Some other optional fields are not present, including some fields from the full HL7 standard not defined in this document because they are not used by NESIIS. Fields not present do not diminish the number of "|" delimiters, so later fields can be identified by ordinal position in the segment. Two NK1 segments give some information for George's mother and father, just the minimum required for his father, with address and telephone fields for his mother.

The PID segments in the third messages give a NESIIS client ID in field PID-3. This must have been transmitted earlier from NESIIS to Valley Clinic's system. In this case it is legitimate to omit more of the optional PID fields, since NESIIS must have at least the minimum required information for these clients even to create a record. However, if there is a possibility that Valley Clinic has new or changed information to send to NESIIS, these fields should be present, and it does no harm to repeat fields even if they have been transmitted previously.

NESIIS answers the file from the above example with a file of ACK messages. Valley Clinic's message 00000123 had the value AL in field MSH-16, asking for acknowledgements of all messages. The value AA in MSA-1 indicates that this message was rejected. The next message, 00000124, uses the value ER to ask for acknowledgement only in case of errors, so this message is acknowledged implicitly by the absence of an MSA Message Acknowledgment Segment for it. This example while legitimate is for purposes of illustration and most providers will probably prefer to follow the NESIIS recommendation of error acknowledgements only. The last message, 00000125, did contain an error, and the ERR segment in its acknowledgement indicates the segment ID (RXA) of the segment, the line number (15) where it appears in the input file, the errant field (10)and the field component (0). The MSA segment contains the error message. Errors will be generated for missing required data, invalid data or any other deviance from the form and content of messages as specified in this document. If all three messages in the first file above had requested error acknowledgement only and none had any errors, then the answering file from NESIIS would contain just the FSH, BHS, MSH, BTS, and FTS segments. All the messages would be implicitly acknowledged as successfully processed.

In the sample file exchange above, the outside system initiated the exchange with the file of VXU segments and NESIIS responded with ACK segments. The format is identical when NESIIS sends VXU segments out and the ACK responses are similar, too. In the MSH segment, the values of the fourth and sixth fields are reversed to show sender and receiver. NESIIS always sends its own client identifier in the required field PID-3 and includes the outside system's identifier in PID-3 if known. Outside systems are encouraged to store NESIIS's client ID, and use it in PID-03 when sending to NESIIS. This provides a firm basis for client identification makes processing easier for the NESIIS system and avoids errors in storing client information, such as creation of duplicate records when an insufficiently identified client record cannot be matched with a record already in the NESIIS database. Though NESIIS makes a great effort to match client records effectively, use of the NESIIS client ID is the best guarantee of clean and useful data.

Real-time Processing

Real-time Processing

Meaningful Use Stage 2 and above requires facilities to automate their data exchange submissions with NESIIS. In Stage 2 this requirement is one-way and in Stage 3 it moves to a two-way relationship with the facility EHR having the ability to query NESIIS.

NESIIS has these abilities and uses true bi-directional exchange with some facilities already. The methods used to automate the connection are either:

PHINMS – a small sending service installed at the client site (or EHR hub); full install and configuration provided by NESIIS resources. PHINMS is also ebXML version 2.0 compliant, and it is possible to connect to NESIIS via an ebXML client masquerading as a PHINMS service.

SOAP Web Services – NESIIS added this option in early 2013 after CDC recommendations to move beyond PHINMS to something more standardized.

Automation of data exchange is worked on only after a thorough testing of files by the submitter. Once this is completed, instructions specific to the service chosen (PHINMS or SOAP) will be provided by NESIIS data exchange staff.

The following section outlines the various message types that are sent in real-time files.

Real-time files that provider organizations send to the NESIIS can contain any of the following message types.

Real-time Process Message Types

VXU^V04^VXU V04

Profile: Z22^CDCPHINVS

Unsolicited Immunization Update
MSH Message Header

PID Patient Identifier Segment
[PD1] Patient Demographic Segment

[{NK1}] Next of Kin Segment [{ Begin Order Group {ORC} Order Request Segment

RXA Pharmacy/Treatment Administration Segment (at least ONE RXA is REQUIRED by NESIIS)

[RXR] Pharmacy/Treatment Route Segment (Only one RXR per RXA segment)

[{ Begin Observation Group OBX Observation Result Segment

[NTE} Observation Note
}] End Observation Group
}] End Order Group

QBP^Q11^QBP_Q11

Profile: Z34^CDCPHINVS

Request Complete Immunization History

MSH Message Header Segment
QPD Input Parameter Specification
RCP Response Control Parameter

Profile: Z44^CDCPHINVS

Query by Parameter (QBP)

MSH Message Header Segment
QPD Input Parameter Specification
RCP Response Control Parameter

RSP^K11^RSP K11

Response to Vaccination Query

Real-time (response) files that the NESIIS sends to provider organizations can contain any of the following message Profiles (specified in MSH-21 of the RSP^K11^RSP_K11 Message):

Profile: Z32^CDPHINVS

Return Complete Immunization History (Returning Exact PID Match)

Profile (specified in MSH-21)

MSH Message Header Segment (One per message)

MSA Message Acknowledgment Segment (One per message)

[ERR] Error Segment

QAK Query Acknowledgment Segment (One per message)
QPD Input Parameter Specification (One per message)
PID Patient Identifier Segment (One per matching client)

[PD1] Patient Demographic Segment

[{NK1}] Next of Kin Segment (Optional, zero or more per matching client)

[{ Begin Order Group ORC Order Request Segment

RXA Pharmacy/Treatment Administration Segment

[RXR] Pharmacy/Treatment Route Segment
[{ Begin Observation Group

Begin Observation Group
OBX Observation Result Segment

[NTE] Observation Note
} End Observation Group
}] End Order Group

Profile: Z31^CDCPHINVS

Return a List of Candidates (Returning Multiple PID Matches)

Profile (specified in MSH-21)

MSH Message Header Segment (One per message)

MSA Message Acknowledgment Segment (One per message)

[ERR] Error Segment

QAK Query Acknowledgement Segment
QPD Input Parameter Specification
Begin patient identifier list

PID Patient Identification Segment (One per matching client)

[PD1] Patient Demographic Segment

[{NK1}] Next of Kin Segment (Optional, zero or more per matching client)

End patient identifier list

Profile: Z33^CDCPHINVS

Return Response with No Matches or More than Maximum Matches

Profile (specified in MSH-21)

MSH Message Header Segment (One per message)

MSA Message Acknowledgment Segment (One per message)

[ERR] Error Segment

[QAK] Query Acknowledgment Segment QPD Input Parameter Specification

Profile: Z23^CDCPHINVS

Return an Acknowledgment

MSH Message Header Segment

MSA Message Acknowledgment Segment

[{ERR}] Error Segment

Profile: Z42^CDCPHINVS

RSP – Return Complete Immunization History and Forecast (paired with Z44)

MSH Message Header Segment

MSA Message Acknowledgment Segment

[ERR] Error Segment

QAK Query Acknowledgement Segment
QPD Input Parameter Specification
PID Patient Identification Segment

Immunization History and Forecast Group

ORC Order Request Segment

RXA Pharmacy/Treatment Administration Segment

[RXR] Pharmacy/Treatment Route Segment

[{ Begin Observation Group OBX Observation Result Segment }] End Observation Group End Order Group

This document outlines the rules/specifications needed to construct an HL7 message. These same rules must be applied for Real-time message processing. **Note: Batch Message Headers (i.e. FHS, BHS) and footers (i.e. FTS, BTS) are NOT required for Real-time processing.

Real-time Process Message Segments

The message segments below are needed to construct message types that are used by NESIIS. Each segment is given a brief description excerpted from the HL7 standard. The tables define what fields make up each segment. Since NESIIS does not use all the fields that HL7 defines, there are sometimes gaps in the ordinal sequence of fields. Following HL7 rules, the gaps do not diminish the number of field separators within the segment. For example, if the second and third fields in a segment are not present, their field separators remain in order to indicate that the next field present is the fourth: field1|||field4.

MSH Segment

Message Header Segment

For VXU and QBP message types, the MSH segment must be constructed according to normal HL7 format specifications (refer to Pg. 5 of this document). For Real-time processing, NESIIS limits the number of MSH segments that can be processed in a single file. Files containing more than 1000 MSH segments will be rejected and an ACK message will be generated, informing the provider that 1000 is the maximum number of MSH segments that NESIIS accepts for Real -time processing.

1. VXU^V04^VXU_V04 (Unsolicited Vaccination Record Update)

As stated earlier in this document, the VXU message is used for sending client demographic and immunization specific data. This message type can be sent via Real-time. VXU segments should be constructed according to normal HL7 format specifications (refer to pages 5-17 of this document). A VXU message must be received in HL7 2.4 or HL7 2.5.1 format for Real-time processing. NESIIS validates the version by reading the MSH-12 field. A VXU message must contain |2.5.1| in MSH-12 for HL7 2.5.1 Querying.

Immunization deletions can be submitted for both batch HL7 2.5.1 and Real-time submissions. To indicate a deletion, the RXA-21 field <u>must</u> be populated with a value of "D". Below is an example of a RXA deletion segment. If the number of deletions received through batch exceeds 5% of the total number of immunizations or more than 50 immunizations are marked for deletion, NESIIS will reject the file. Providers are only able to delete immunizations that were entered by their organization.

```
RXA|0|999|19860715|19860715|00006-4133-41^10 pack-1 dose vials^NDC |0||05^^^^||^^208^^^^^|||||||||D|
```

Note: For updates and additions, organizations shall use a value of "A" for additions in RXA-21, NESIIS has specific criteria for determining whether to update the record or add a new immunization. It is important to not assume Updates will be or need to be specifically indicated.

2. QBP^Q11_QBP^Q11 (Query for Vaccination Record)

MSH-21 should contain Z34^CDCPHINVS or Z44^CDCPHINVS.

When a health care provider (participating in an immunization registry) needs to obtain a complete patient vaccination record, a QBP (query) is sent to the immunization registry for the definitive (last updated) immunization record. The three segments that make up a QBP message are the MSH (message header), QPD (query parameter definition), and RCP (response control parameter). For a QBP message, the MSH-9 field must contain |QBP^Q11^QBP_Q11| and the segments must be in the following sequence order:

```
MSH|^~\&|||||20100824||QBP^Q11^QBP_Q11|MyMessageId|P^|2.5.1^^|||ER||||||Z34^CDCPHINVS QPD|Z34^Request Immunization
History^HL70471|Qry 01|1^^^PI^|LAST^FIRST^MIDDLE|MAIDEN^MOTHER|19620119|F|||
```

The QPD are outlined in detail below.

OPD Segment

Query Parameter Definition Segment

Used to define a query. The QPD segment defines the parameters of the query. This segment is intentionally very similar to the PID segment containing permanent patient identifying and demographic information that, for the most part, is not likely to change frequently.

SEQ	LEN	DT	R/O	RP/#	TBL#	ELEMENT NAME
1		CE	R			Message Query Name
2	32	ST	R			Query Tag
3		CX	R	Υ		Patient Identifier List
4		XPN-M	R			Patient Name
5		XPN	RE			Mother's Maiden Name
6	26	TS	R			Patient Date of Birth
7	1	IS	RE			Patient Sex
8		XAD	RE			Patient Address
9		XTN	RE			Patient Home Phone Number
10	1	ID	RE			Patient Multiple Birth Indicator
11	2	NM	RE			Patient Birth Order
12		TS	RE			Client Last Updated Date
13		HD	RE			Client Last Update Facility

Field Notes:

- QPD-1 Use either "Z34^Request Complete Immunization History^CDCPHINVS," or "Z44^Request Evaluated Immunization History^CDCPHINVS."
- QPD-2 Unique to each query message instance.
- QPD-3 This is a required field. Sub-components 1 (ID), 4 (assigning authority see Table 0363), and 5 (identifier type code see Table 0203) are required in the QPD-3 field. When a Provider Organization is sending to NESIIS, use the sending system's Char Number or other identifier if available.
- QPD-4 This is a required field. See the XPN data type. Last name and first name are required in the first two components. If the Name Type Code component is included, use L-Legal.
 NOTE: If client does not have a first name, NO FIRST NAME must be entered. NESIIS does not support repetition of this field.
- QPD-5 See the XPN data type. In this context, where the mother's name is used for client identification, NESIIS uses only last name and first name. If not valued, Mother's maiden name is not considered when seeking matching clients.
- QPD-6 This is a required field, contains the client's date of birth (YYYYMMDD). NESIIS ignores any time component.
- QPD-7 This field contains the client's sex. Refer to Use-defined Table 0001 Administrative sex for suggested values. Use F, M, or U.
- QPD-8 This field contains the address of the client. See XAD data type. NESIIS does not support repetition of this field.
- QPD-9 This field contains the client's personal phone numbers. Refer to HL7 Table 0201 Telecommunication Use Code and HL7 Table 0202 Telecommunication Equipment Type for valid values. Ignored by NESIIS because phone number is not one of the fields used for client matching.
- QPD-10 Use Y to indicate that the client was born in a multiple birth.
- QPD-11 Relevant when client was born in a multiple birth. Use 1 for the first born, 2 for the second, etc. This field is useful in matching client data to existing records.
- QPD-12 If this value is not populated, then client last updated date is not considered when seeking matching clients.
- QPD-13 If this value is not populated, then client last updating facility is not considered when seeking matching clients.

Example:

MSH|^~\&||||||QBP^Q11^QBP_Q11|793543|P|2.5.1||||||||Z34^CDCPHINVS <CR>

QPD| Z34^Request Immunization History^HL70471

|37374859|123456^^MYEHR^MR|Child^Bobbie^Q^^^L|Que^Suzy^^^M|20050512|M|10 East Main St^Myfaircity^GA^^L<CR>

RCP|I|5^RD^HL70126|R^real-time^HL70394<CR>

This query is being sent from a system with a name space identifier of MYEHR. It is requesting an immunization history for a person named Bobbie Q Child. His mother's maiden name was Suzy Que. He was born 5/12/2005 and lives at 10 East Main St, Myfaircity, Georgia. His medical record number with MYEHR is 12345. The most records that the requesting system wants returned if lower confidence candidates are returned is 5. Processing is expected to be "immediate".

RCP Segment

Response Control Parameter Segment

The required RCP segment is used to restrict the amount of data that should be returned in response to query. It lists the segments to be returned. In addition to fields one and two, the CDC IG includes definitions for fields three through seven. This guide does not include definitions for fields three through seven because NESIIS does not parse/use those fields.

SEQ	LEN	DT	R/O	RP/#	TBL#	ELEMENT NAME
1	1	ID	RE		0091	Query Priority
2		CQ	RE			Quantity Limited Request

Field Notes:

- RCP-1 This field contains the time frame that the response is expected. Refer to HL7 Table 0091 query priority for valid values. Table values and subsequent fields specify time frames for response. Only **I** for immediate shall be used for this field. NESIIS defaults to I if this field is left empty.
- RCP-2 This field contains the maximum length of the response that can be accepted by the requesting system. Valid entries are numerical values (in the first component) given with the units specified in the second component. NESIIS requires RD in the second component. If blank, value defaults to "10."

Note: This field is the maximum total records to return. The Version 2.5.1 standard indicates the maximum number to return in each batch. No batching of responses is permitted in this Guide.

QAK Segment

Query Acknowledgment Segment

The Required Query Acknowledgment (QAK) segment contains information sent in an RSP message. It cannot be repeated.

SEQ	LEN	DT	R/O	RP/#	TBL#	ELEMENT NAME
1	32	ST	R			Query Tag
2	2	ID	R		0208	Query Response Status
3		CE	R			Message Query Name

Field Notes:

- QAK-1 Query Tag. Echoes the QPD-2 Query Tag query identifier sent by the organization requesting information through a QBP message. With this value, NESIIS matches the RSP message to the query.
- QAK-2 Query Response Status. This field allows the responding system to return a precise response status. It is especially useful in the case where no data is found that matches the query parameters, but where there is also no error. It is defined with HL7 Table 0208 Query Response Status.
- QAK-3 Message Query Name. Echoes the QPD-1 Message Query Name sent by the organization requesting information through a QBP message.

Example: Z33^CDCPHINVS Response profile (No client match found)

MSH|^~\&|NESIIS^^||NESIIS^^|||20110330||RSP^K11^RSP_K11|PHIN_QUERY01|P^|2.5.1^^|||ER||||||**Z33^CDCPHINVS** MSA|AA|PHIN_QUERY01

QAK|PHIN_QUERY01|NF|Z343^request Immunization history^HL70471

 $QPD|Z33^{Request\ Immunization\ History^{HL70471}|PHIN_QUERY_01||Jane^{Doe^{\wedge\wedge\wedge\wedge}L^{\wedge}||20080612|||}$

ACK

Acknowledgment Messages (with Errors)

ACK messages are generated for message rejections and for informational error messages. Four conditions that result in entire message rejection are:

- 1. Sequencing (i.e. a PID segment must follow an MSH segment).
- 2. Required segment missing.
- 3. Required field missing from the [1..1] must have exactly one occurrence segment (i.e. a blank MSH-9 field, MSH-9 Message Type is a required field in required segment, without valid data, message cannot be processed).
- 4. Required field contains invalid data from the must have exactly one occurrence segment.

An ACK is also generated when an informational error message has occurred, but it has not resulted in message rejection (i.e. NK1 segment contains no last name). In this case, the segment is ignored but the remainder of the message is processed. An ACK message is generated with a message informing the sender of the problem. The error message in this case would NOT include "Message Rejected". The ACK contains the MSH, MSA and ERR segments.

The MSH segment is generated according to normal HL7 processing guidelines. The MSA and ERR segments are detailed below:

ERR Segment

The ERR segment is used to add error comments to acknowledgment messages.

Note: ERR-1 field is not supported in Version 2.5.1.

SEQ	LEN	DT	R/M	RP/#	TBL#	ELEMENT NAME
1			Х			Not supported for Version 2.5 and above.
2	18	ERL	RE			Error Location
3	705	CWE	R	Υ	0357	HL7 Error Code
4		ID	R		0516	Severity
5		CWE	RE		0533	Application Error Code
8		TX	RE			User Message

Field Notes:

ERR-2 Error Location. Identifies the location in a message related to the identified error, warning or message. Each error will have an ERR, so no repeats are allowed on this field. This field may be left empty if location is unable to be parsed.

ERR-3 HL7 Error Code. Identifies the HL7 error code. Refer to HL7 Table 0357 – Message Error Condition Codes for valid values.

ERR-4 Identifies the severity of an application error. The Severity code indicates if the system sending the ACK or RSP (with error) is reporting an error that caused significant error loss. Refer to HL7 Table 0516.

ERR-5 Application specific code identifying the specific error that occurred. Refer to User-defined Table 0533 for appropriate values. Segment 1 (identifier) is required.

ERR-8 Error Message. This optional field further describes an error condition in HL7 2.5.1 ACK message. When a message has been rejected, NESIIS generates "Message Rejection" as the first portion of the test describing the error message. Informational messages will not contain "Message Rejection".

MSA Segment

Message Acknowledgment Segment

SEQ	LEN	DT	R/O	RP/#	TBL#	ELEMENT NAME
1	2	ID	R		8000	Acknowledgment code
2	20	ST	R			Message control ID
3	80	ST	0			Text message
4	15	NM	0			Expected sequence number
5	1	ID	0		0102	Delayed acknowledgment type
6	100	CE	0		0357	Error condition

Field Notes:

MSA-1 The acknowledgment code indicates whether the message was accepted, rejected, error, etc...This is a required field. NESIIS generates an "AR" for messages resulting in rejection errors. An "AE" is generated for informational errors. An "AA" is generated for processed normally.

Note: For backwards compatibility, NESIIS generates an "AR" for all rejections, including but not limited to:

- Unsupported Message Type
- Unsupported Event Code
- Unsupported Processing ID
- Unable to process for reasons unrelated to format or content.
- MSA-2 The message control ID is the unique ID that is sent by the sending system. This is a required field. It allows the sending system to associate each message with a response. In a response, this will be the same as the control ID that was sent in MSH-10 by the sending system.
- MSA-3 This optional field further describes an error condition. When a message has been rejected, NESIIS generates "Message Rejection" as the first portion of the text describing the error message. Informational messages will not contain "Message Rejection".
- MSA-4 This optional numeric field is used in the sequence number protocol. NESIIS does not generate this field.
- MSA-5 Delayed Acknowledgement type. NESIIS does not generate this field.
- MSA-6 Error Condition. Refer to HL7 table 0357 for possible values.

This concludes real-time processing.

Appendix A -- HL7 Data Types

The following descriptions of HL7 data types are excerpted or adapted from the HL7 standard. See the field notes within each segment definition above on how to use data types in particular fields. Some data types have complex definitions much of which does not apply to NESIIS usage, and for these we omit much of the HL7 definition of the data type, referring instead to the field notes in the segment definitions.

CE -- Coded Element (most uses)

Components: <identifier (ST)> ^ <text (ST)> ^ <name of coding system (ST)> ^ <alternate identifier (ST)> ^ <alternate identifi

Example:

```
|F-11380^CREATININE^I9^2148-5^CREATININE^LN|
```

This data type transmits codes and the text associated with the code. To allow all six components of a CE data type to be valued, the maximum length of this data type must be at least 60.

• Identifier (ST)

Sequence of characters (the code) that uniquely identifies the item being referenced by the <text>. Different coding schemes will have different elements here.

Text (ST)

Name or description of the item in question. E.g., myocardial infarction or X-ray impression. Its data type is string (ST).

• Name of Coding System (ST)

Each coding system is assigned a unique identifier. This component will serve to identify the coding scheme being used in the identifier component. The combination of the **identifier** and **name of coding system** components will be a unique code for a data item. Each system has a unique identifier. ASTM E1238-94, Diagnostic, procedure, observation, drug ID, and health outcomes coding systems are identified in the tables in Section 7.1.4 [of the full HL7 standard], "Coding schemes." Others may be added as needed. When an HL7 table is used for a CE data type, the *name of coding system* component is defined as *HL7nnnn* where *nnnn* is the HL7 table number.

• Alternate Components

These three components are defined analogously to the above for the alternate or local coding system. If the Alternate Text component is absent, and the Alternate Identifier is present, the Alternate Text will be taken to be the same as the Text component. If the Alternate Coding System component is absent, it will be taken to mean the locally defined system.

Note: The presence of two sets of equivalent codes in this data type is semantically different from a repetition of a CE-type field. With repetition, several distinct codes (with distinct meanings) may be transmitted.

Note: For HL7-defined tables which have not been adopted from some existing standard, the third component, "name of coding system," is constructed by appending the table number to the string "HL7." Thus, the field *RXR-2-site*, is a CE data type which refers to HL7 table number 0163. Its "name of coding system" component is "HL70163".

<u>CQ – Composite Quantity with Units</u>

This data type carries a quantity and attendant units. Its primary use in here will be for indicating the maximum number of records to return in a query response.

Example:

|10^RD| indicates 10 records.

• Quantity (NM)

Specifies the numeric quantity or amount of an entity.

Units (CE)

Specifies the units in which the quantity is expressed..

<u>CE_TX – Text only CE data type</u>

This data type is used to transmit text-only notes in RXA-9 (Administration Notes). When transmitting a text note in RXA-9, only the first triplet should be populated.

<u>CWE - Coded with Exceptions</u>

Components: <Identifier (ST)> ^ <text (ST) ^ <Name of Coding (ID)> ^ <Alternate Identifier (ST) ^ <Alternate Text (ST) ^ <Name of Alternate (ID)> ^ <Coding System Version ID (ST)> ^ <Alternate Coding System Version ID (ST)> ^ <Original Text (ST)>

Subcomponents of facility (HD): <namespace ID (IS)> & <universal ID (ST)> & <universal ID type (ID)>

From RXR: |C28161^IM^NCIT^IM^INTRAMUSCULAR^HL71062|

• Identifier (ST)

Sequence of characters (the code) that uniquely identifies the item being referenced by the <text>. Different coding schemes will have different elements here.

Text (ST)

Name or description of the item in question. E.g., myocardial infarction or X-ray impression. Its data type is string (ST).

• Name of Coding System (ST)

Each coding system is assigned a unique identifier. This component will serve to identify the coding scheme being used in the identifier component. The combination of the **identifier** and **name of coding system** components will be a unique code for a data item. Each system has a unique identifier. ASTM E1238-94, Diagnostic, procedure, observation, drug ID, and health outcomes coding systems are identified in the tables in Section 7.1.4 [of the full HL7 standard], "Coding schemes." Others may be added as needed. When an HL7 table is used for a CE data type, the *name of coding system* component is defined as *HL7nnnn* where *nnnn* is the HL7 table number.

CX – Extended Composite ID with Check Digit

NESIIS uses this data type only for client identification in Patient Identification (PID) segments. See the field notes for values used for NESIIS.

<u>DT_D - Date with Precision to Day</u>

This data type specifies the century and year with optional precision to month and day

DTM - Date/Time

The number of characters populated (excluding the time zone specification) specifies the precision. Format: YYYY[MM[DD[HH[MM[SS[.S[S[S]]]]]]]]+/-ZZZZ]

- Eight are used to specify a precision of "day."
- the first ten are used to specify a precision of "hour."
- the first twelve are used to specify a precision of "minute."
- the first fourteen are used to specify a precision of "second."
- the first sixteen are used to specify a precision of "one tenth of a second."
- the first nineteen are used to specify a precision of "one ten thousandths of a second.

When the time zone is not included, it is presumed to be the time zone of the sender.

Example: [199904] specifies April 1999.

Note that this date type will be constrained at the field level, depending on the use.

EI – Entity Identifier

The Entity Identifier (EI) data type defines an entity within a specific series.

The four EI components specify an entity in a series <entity identifier (ST)>^<namespace ID (IS)>^<universal ID (ST)>^<universal ID type (ID)> For example, |z31^CDCPHINVS| in MSH-21.

• Entity Identifier (ST)

A unique identifier from a series of identifiers.

• Namespace ID (IS)

A user-defined identifier that specifies the assigning authority responsible for the data.

• Universal ID (ST)

The unique Object Identifier (OID) within the defined Universal ID Type. It must follow the Universal ID Type syntactic rules. If populated, this component should be an OID.

• Universal ID Type (ID)

Controller of Universal ID deciphering. If a Universal ID exists, this element should be the value ISO.

ERL – Error Location

The Error Location (ERL) data type identifies exactly where an error occurred.

The six ERL components specify where an error occurred

<segment ID (ST)>^<segment sequence (NM)>^<field position (NM)>^<field repetition (NM)>^<component number (NM)>

For example, |RXA^1^5^1^3|

• Segment ID (ST)

The three-letter code that names the segment category.

• Segment Sequence (NM)

Identifies the specific instance of the segment where the error occurred. These numbers use 1 for the first instance, 2 for the second, and so forth.

• Field Position (NM)

Determines the field number within the segment. These numbers use 1 for the first field, 2 for the second, and so forth. NESIIS leaves the field number empty when referring to the entire segment as a whole.

• Field Repetition (NM)

The first instance uses 1. If the Field Position is populated, then NESIIS values the Field Repetition.

• Component Number (NM)

Determines the component number within the field. These numbers use 1 for the first component, 2 for the second, and so forth. NESIIS leaves the Component Number empty when referring to the entire field as a whole.

• Sub-Component Number (NM)

Determines the Sub-Component number within the component. These numbers use 1 for the first component, 2 for the second, and so forth. NESIIS leaves the Component Number empty when referring to the entire field as a whole.

FN – Family Name

This data type contains a person's family name (i.e. surname). Surname (ST) – This is the person's last name.

FT – Formatted Text (new)

Usage Note: The FT data type allows use of the formatting escape sequences documented in *HL7 Version 2.5.1, Chapter 2, Section 2.7.1 - Use of Escape Sequences in Text Fields.* In this implementation guide, the only allowed escape sequences are those allowed in *HL7 Version 2.5.1, Chapter 2, Section 2.7.4 - Special Characters.* These are the escape sequences for the message delimiters (i.e., |^&~\).

HD -- Hierarchic Designator

The Hierarchic Designator (HD) determines the organization or system responsible for managing or assigning a defined identifier set. NESIIS uses this data type only to identify sender and receiver in Message Header (MSH) segments. See the field notes for values used for NESIIS.

The three HL components establish the entity responsible for defined identifiers <namespace ID (IS)>^<universal ID (ST)>^<universal ID type (ID)>

For example, |NESIIS7.3.1|

ID -- Coded Values for HL7 Defined Tables

The value of such a field follows the formatting rules for a ST field except that it is drawn from a table of legal values. There shall be an HL7 table number associated with ID data types. Examples of ID fields include religion and sex. This data type should be used only for HL7 tables. The reverse is not true, since in some circumstances it is more appropriate to use the CE data type for HL7 tables.

IS -- Coded Values for User Defined Tables

The value of such a field follows the formatting rules for a ST field except that it is drawn from a site-defined (or user-defined) table of legal values. There shall be an HL7 table number associated with IS data types. An example of an IS field is the *Event reason code* defined in Section 3.3.1.4 [of the full HL7 standard], "Event reason code." This data type should be used only for user-defined tables. The reverse is not true, since in some circumstances, it is more appropriate to use the CE data type for user-defined tables.

LA2 - Location with Address Variation 2

The Location with Address Variation 2 (LA2) specifies a location and its address.

```
The sixteen LA2 components specify a location <point of care (IS)> ^ <room (IS) ^ <bed (IS)> ^ <facility (HD) ^ <location status (IS) ^ <patient location type (IS)> ^ <building (IS)> ^ <floor (IS)> ^ < street address (ST)> ^ <other designation (ST)> ^ <city (ST)> ^ <state or province (ST)> ^ <zip or postal code (ST)> ^ <country (ID)> ^ <address type (ID)> ^ <other geographic designation (ST)> For example, |^^2345^^^15^101 MAIN STREET^^METROPOLIS^NE|
```

MSG – Message Type

This field contains the message type, trigger event, and the message structure ID for the message in MSH-9 Message Type.

The three MSH components define the message type

<message code (ID)>^<trigger event (ID)>^<message structure (ID)>

For example, |VXU^V04^VXU_V04|

NM -- Numeric

A number represented as a series of ASCII numeric characters consisting of an optional leading sign (+ or -), the digits and an optional decimal point. In the absence of a sign, the number is assumed to be positive. If there is no decimal point the number is assumed to be an integer. Examples:

```
|999|
|-123.792|
```

Leading zeroes, or trailing zeroes after a decimal point, are not significant. For example, the following two values with different representations, "01.20" and "1.2", are identical. Except for the optional leading sign (+ or -) and the optional decimal point (.), no non-numeric ASCII characters are allowed. Thus, the value <12 should be encoded as a structured numeric (SN) (preferred) or as a string (ST) (allowed, but not preferred) data type.

PT – Processing Type

This data type indicates whether to process a message as defined in HL7 Application (level 7) Processing rules.

Processing ID (ID)

A value that defines whether the message is intended for a production, training, or debugging system. Refer to HL7 Table 0103 – Processing ID for valid values.

SAD - Street Address

The street address (SAD) specifies an entity's street address and associated details.

The three SAD components contain address details <street or mailing address (ST)>^<street name (ST)>^<dwelling number (ST)> For example, |747 ABERG^^Albany^NE^68352 |

• Street or Mailing Address (ST)

For a person or institution, states the first line of a street or mailing address.

SI -- Sequence ID

A non-negative integer in the form of a NM field. See the field notes in segments using this data type for specifications of SI fields.

ST -- String Data

String data is left justified with trailing blanks optional. Any displayable (printable) ACSII characters (hexadecimal values between 20 and 7E, inclusive, or ASCII decimal values between 32 and 126), except the defined delimiter characters. Example:

|almost any data at all|

To include any HL7 delimiter character (except the segment terminator) within a string data field, use the appropriate HL7 escape sequence.

Usage note: the ST data type is intended for short strings (e.g., less than 200 characters). For longer strings the TX or FT data types should be used.

TS – Time Stamp

Format: YYYY[MM[DD[HHMM[SS[.S[S[S]]]]]]]]+/-ZZZZ]^<degree of precision>

Contains the exact time of an event, including the date and time. The date portion of a time stamp follows the rules of a date field and the time portion follows the rules of a time field. NESIIS ignored any time component. Precision must be at least to the day.

The two TD components carry time and precision

<time (DTM)>^<degree of precision (ID)>

For example, |20010902|

TS M - Time Stamp with Optional Precision to the Day and No Time Zone

Specifies a point in time. This data type requires a precision to the month. Precision to the day is optional.

TS NZ - Time Stamp with Optional Precision to the Day and No Time Zone

Specifies a point in time. This data type requires a precision to the day. No Time zone is included. NESIIS ignores any time component.

TS Z – Time Stamp Requiring Time Zone

Specifies a point in time. This data type requires a precision to the second and requires that the time zone be included.

VID – Version Identifier

This specifies the HL7 version.

XAD – Extended Address

Components: <street address (SAD)> ^ <other designation (ST)> ^ <city (ST)> ^ <state or province (ST)> ^ <zip or postal code(ST)> ^ <country (ID)> ^ < address type (ID)> ^ <other geographic designation (ST)>^ <country/parish code (IS)> ^ <census tract (IS)> ^ <address representation code (ID)>

Example:

|1234 Easy St.^Ste. 123^San Francisco^CA^95123^USA^B^^SF^^|

• Street Address (SAD)

The street or mailing address of a person or institution.

• Other Designation (ST)

Second line of address. In general, it qualifies address. Examples: Suite 555 or Fourth Floor.

• City (ST)

City address of a person or institution

• State or Province (ST)

State or province should be represented by the official postal service codes for that country.

• Zip or Postal Code (ST)

Zip or postal codes should be represented by the official codes for that country. In the US, the zip code takes the form 99999[-9999], while the Canadian postal code takes the form A9A-9A9.

Country (ID)

Defines the country of the address. See Table 0212.

• Address Type (ID)

Address type is optional.

• County/Parish Code (IS)

A code that represents the county in which the specified address resides. Refer to *user-defined table 0289 - County/parish*. When this component is used to represent the county (or parish), component 8 "other geographic designation" should not duplicate it (i.e., the use of "other geographic designation" to represent the county is allowed only for the purpose of backward compatibility, and should be discouraged in this and future versions of HL7).

XCN -- Extended Composite ID Number and Name for Persons

NESIIS uses this data type only to identify Provider Organizations that administer immunizations. See the field notes for segment RXA.

XPN -- Extended Person Name

```
Components: <family name (ST)> & <last name prefix (ST)> ^< <given name (ST)> ^< <middle initial or name (ST)> ^< <suffix (e.g., JR or III) (ST)> ^< <prefix (e.g., DR) (ST)> ^< <degree (e.g., MD) (ST)> ^< <name type code (ID) > ^< <name representation code (ID)>
```

Example:

|Smith&St^John^J^III^DR^PHD^L|

• Family Name (FN)

Usually the last name.

Note: The Given Name (first name), Family Name (last name), and Second and Further Given Names or Initials Thereof cannot contain special characters. NESIIS accepts letters; spaces; and period., hyphen -, and apostrophe characters.

• Given Name (ST)

Usually the first name.

• Second and Further Given Names or Initials Thereof (ST)

Usually the middle name or initial, if available. Multiple Second and Further Given Names or Initials Thereof may be included by separating them with spaces.

• Name Type Code (ID)

Given information like maiden name, legal name, etc. If the field is empty, NESIIS defaults to L for Legal Name.

• Suffix (ST)

Used to specify a name suffix (e.g., Jr. or III).

• Prefix (ST)

Used to specify a name prefix (e.g., Dr.).

• Degree (ST)

Used to specify an educational degree (e.g., MD).

• Name Type Code (ID)

A code that represents the type of name. Refer to HL7 table 0200 - Name type for valid values.

Table 0200 - Name type

Value	Description
A	Alias Name
L	Legal Name
D	Display Name
M	Maiden Name
С	Adopted Name

Note: The legal name is the same as the current married name.

• Name Representation Code (ID)

This component can be used when names are represented in ideographic or non-alphabetic systems. NESIIS ignores this component.

XON - Extended Composite Name and ID Number and Name for Organizations

This data type identifies an organization using a unique id and name. The ID is associated with an entity such as an organization, which assigns the ID.

XPN M - Extended Person Name - Maiden Name

This is used for representing a mother's maiden name

XTN – Extended Telecommunication Number

Extended Telecommunication Number

Components: [NNN] [(999)]999-9999 [X99999] [B99999] [C any text] ^ <telecommunication use code (ID)> ^ <telecommunication equipment type (ID)> ^ <tenail address (ST)> ^ <tountry code (NM)> ^ <area/city code (NM)> ^ <phone number (NM)> ^ <extension (NM)> ^ <any text (ST)>

Example:

(415)555-3210^ORN^FX^

• [(999)] 999-9999 [X99999] [C any text]

Defined as the TN data type, except that the length of the country access code has been increased to three.

• Telecommunication use code (ID)

A code that represents a specific use of a telecommunication number. Refer to HL7 table 0201 - Telecommunication use code for valid values.

Table 0201 - Telecommunication use code

Value	Description	
PRN	Primary Residence Number	
ORN	Other Residence Number	
WPN	Work Number	
VHN	Vacation Home Number	
ASN	Answering Service Number	
EMR	Emergency Number	
NET	Network (email) Address	
BPN	Beeper Number	

• Telecommunication equipment type (ID)

A code that represents the type of telecommunication equipment. Refer to HL7 table 0202 - Telecommunication equipment type for valid values.

Table 0202 - Telecommunication equipment type

Value	Description	
PH	Telephone	
FX	Fax	
MD	Modem	
СР	Cellular Phone	
BP	Beeper	
Internet	Internet Address: Use Only If Telecommunication Use Code Is NET	
X.400	X.400 email address: Use Only If Telecommunication Use Code Is NET	

Email address (ST) Country code (NM) Area/city code (NM) Phone number (NM) Extension (NM) Any text (ST)

Appendix B -- HL7 Tables

The following tables give valid values for fields in the segments defined above, in the cases where the field definitions reference an HL7 table number. The tables are considered to be part of the HL7 standard, but those tables designated as type User have values determined by NESIIS.

Туре	Table	Name	Value	Description
HL7	0001	Sex		
	0001		F	Female
	0001		M	Male
	0001		U	Unknown
HL7	0003	Event Type		O I I I I I I I I I I I I I I I I I I I
,	0003		A31	ADT/ACK - Update patient information
	0003		K11	RSP- Response to vaccination query (Real-Time)
	0003		Q11	QBP - Query for vaccination record (Real-Time)
	0003		V04	VXU - Unsolicited vaccination record update
HL7	0004	Patient class		VAC Chochoice vaccination record aparate
,	0004		R	Recurring
HL7	0005	Race		roodining
1127	0005		1002-5	American Indian or Alaska Native
	0005		2028-9	Asian
	0005		2076-8	Native Hawaiian or Other Pacific Islander
	0005		2054-5	Black or African-American
	0005		2106-3	White
	0005		2131-1	Other Race
	0005		Null	Unknown
HL7	0008	Acknowledgment Code	Itali	Olikiowii
1127	0008	I I I I I I I I I I I I I I I I I I I	AA	Application Accept
	0008		AE	Application Error
	0008		AR	Application Reject
User	0063	Relationship	741	Application reject
0001	0063		ASC	Associate
	0063		BRO	Brother
	0063		CGV	Care giver
	0063		CHD	Child
	0063		DEP	Handicapped dependent
	0063		DOM	Life partner
	0063		EMC	Emergency contact
	0063		EME	Employee
	0063		EMR	Employer
	0063		EXF	Extended family
	0063		FCH	Foster Child
	0063		FND	Friend
	0063		FTH	Father
	0063		GCH	Grandchild
	0063		GRD	Guardian
	0063		GRP	Grandparent
	0063		MGR	Manager
	0063		MTH	Mother
	0063		NCH	Natural child
	0063		NON	None
	0063		OAD	Other adult
	0063		ОТН	Other
	0063		OWN	Owner
	0063		PAR	Parent
	0063		SCH	Stepchild
	0003		3011	осеронни

Туре	Table	Name	Value		Description
,	0063		SIB		Sibling
	0063		SIS		Sister
	0063		SPO		Spouse
	0063		TRA		Trainer
	0063		UNK		Unknown
	0063		WRD		Ward of court
HL7	0064	Financial class	WILE		Wald of court
1167	0064	Age: All	V00		VFC eligibility not determined/unknown
	0064	Age: All	V01		Not VFC eligible - Insured
	0064	Age: <19 yrs	V01		VFC eligible – Medicaid/Medicaid Managed Care
	0064	Age: <19 yrs	V02		VFC eligible – Uninsured
	0064	Age: <19 yrs	V03		VFC eligible – American Indian/Alaskan Native
	0064	Age: <19 yrs	V04		
	0004	riger the year	V05		VFC eligible – Federally Qualified Health Center Patient (under-insured)
	0064	Age: >=19 yrs	V07		VFC eligible – Medicaid >19yrs
	0064	Age: >=19 yrs	NE02		Not VFC eligible – Local-specific eligibility 'Medicare'
	0064	Age: >=19 yrs	NE03		Not VFC eligible – Uninsured (Adult)
	0064	Age: >=19 yrs	NE04		Not VFC eligible – Underinsured (Adult)
HL7	0076	Message Type	I TOT		
· ·	0076			General acknowledgment message	
	0076		ADT		ADT message
	0076 AB1			Query by parameter	
	0076		RSP		Segment pattern response
	0076				Unsolicited vaccination record update
HL7	0076	Observation result status	VXO		Onsolicited vaccination record appeare
ΠL/	0005	codes			
	0085	<u>codes</u>	0		Order detail description only
HL7	0003	Query Priority			Order detail description only
1111	0091	Query 111011ty	ı		Immediate
HL7	0103	Processing ID	I		Inmediate
ПЦ	0103	1 Toccssing 1D	Р		Production
LII 7		Version ID	<u> </u>		Froduction
HL7	0104	version 1D	2.2.4		Palance 2.2.4.4000
	0104		2.3.1		Release 2.3.1 1999
	0104		2.4		Release 2.4 2000
	0104		2.5.1		Release 2.5.1 April 2007
HL7	0125	Constrained			
	0125		CE		
	0125		NM		
	0125		ST		
	0125		DT		
	0125				
			ID		
	0125	Yes/No Indicator	TS		
HL7	0136	1 es/1vo indicator	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		V ₂ -
	0136		Y		Yes
–	0136	A 000mt/A12 00 42	N		No
HL7	0155	Accept/Application Acknowledgment Conditions			
	0155		AL		Always
	0155		ER		Error/reject conditions only
	0155		NE		Never
HL7	0162	Route of Administration	HL7 0162	HL7 NCIT	
	0162		ID	C38238	Intradermal
	0.102		, . <u></u>	333200	

Туре	Table	Name	Value		Description
	0162		NS	C38284	Nasal
	0162		IV	C38276	Intravenous
	0162		РО	C38288	Oral
	0162		ОТН		Other/Miscellaneous
	0162		SC	C38299	Subcutaneous
	0162		TD	C38305	Transdermal
	0162		MP	C38676	Percutaneous
HL7	0163	Administrative Site			
	0163		BN		Bilateral Naris
	0163		LT		Left Thigh
	0163		LA		Left Arm
	0163		LD		Left Deltoid
	0163		LG		Left Gluteus Medius
	0163		LVL		Left Vastus Lateralis
	0163		LLFA		Left Lower Forearm
	0163		RA		Right Arm
	0163		RT		Right Thigh
	0163		RVL		Right Vastus Lateralis
	0163		RG		Right Gluteus Medius
	0163		RD		Right Deltoid
	0163		RLFA		Right Lower Forearm
HL7	0189	Ethnic Group			
	0189		2135-2		Hispanic
	0189		2186-5		Non-Hispanic
	0189		Null		Unknown
HL7	0190	Address Type			
	0190		С		Current or temporary
	0190		Р		Permanent
	0190		М		Mailing
	0190		В		Firm/Business
	0190		0		Other
	0190		Н		Home
	0190		N		Birth (nee)
	0190		F		Country of Origin
	0190		L		Legal Address
	0190		BDL		Birth delivery location [use for birth facility]
	0190		BR		Residence at birth [use for residence at birth]
	0190		RH		Registry home
	0190		ВА		Bad address
HL7	0200	Name Type			
	0200		Α		Alias name
	0200		L		Legal name
	0200		D		Display name
	0200		М		Maiden name
	0200		С		Adopted name
	0200		В		Name at birth
	0200		Р		Name of partner/spouse
	0200		U		Unspecified
HL7	0201	<u>Telecommunication use</u> <u>code</u>			
	0201		PRN		Primary residence number
	0201		ORN		Other residence number
	0201		WPN		Work number
	0201		VHN		Vacation home number
	0201		ASN		Answering service number

Туре	Table	Name	Value	Description
	0201		EMR	Emergency number
	0201		NET	Network (e-mail) address
	0201		BPN	Beeper number
HL7	0202	Telecommunication equipment type		
	0202		PH	Telephone
	0202		FX	Fax
	0202		MD	Modem
	0202		СР	Cellular phone
	0202		BP	Beeper
	0202		Internet	Internet address: Use only if telecommunication use code is NET.
	0202		X.400	X.400 email address: Use only if telecommunication use code is NET.
	0202		TDD	Telecommunication Device for the Deaf
	0202		TTY	Teletypewriter
User	0203	Identifier Type		
	0203		ANON	Anonymous identifier
	0203		BR	Birth Registry Number
	0203		DL	Driver's License Number
	0203		HC	Health Card Number
	0203		LR	Local Registry ID
	0203		MA	Medicaid Number
	0203		MC	Medicare Number
	0203		MR	Medical Record Number
	0203		MRT	Temporary Medical Record Number
	0203		NH	National Health Plan Identifier
	0203		NI	
				National Unique Individual Identifier
	0203		PI	Patient Internal Identifier
	0203		PN	Person Number
	0203		PRN	Provider Number
	0203		PT	Patient External Identifier
	0203		RRI	Regional Registry ID
	0203		SR	State Registry Identifier
	0203		SS	Social Security Number
	0203	0 7 9	WC	WIC Identifier
User	0208	Query Response Status		
	0208		OK	Data found, no errors (this is the default)
	0208		NF	No data found, no errors
	0208		AE	Application error
	0208		AR	Application reject
	0208		TM	Too many candidates found
User	0212	<u>Nationality</u>		
	0212		CA	Canada
	0212		US	United States of America
User	0215	Publicity Code		
	0215		01	No reminder/recall
	0215		02	Yes reminder/recall – any method
	0215		03	Reminder/recall – no calls
	0215		04	Reminder only – any method
	0215		05	Reminder only – no calls
	0215		06	Recall only – any method
	0215		07	Recall only – no calls
	0215		08	Reminder/recall – to provider
	0215		09	Reminder to provider
	0215		10	Only reminder to provider, no recall

Туре	Table	Name	Value	Description
	0215		11	Recall to provider
	0215		12	Only recall to provider, no reminder
HL7	0227	Manufacturers of vaccines (code = MVX)		
	0227		AB	Abbott
	0227		AD	Adams
	0227		AKR	Akorn, Inc
	0227		ALP	Alpha
	0227		AR	Armour (Inactive – use ZLB)
	0227		AVB	Aventis Behring (Inactive use ZLB)
	0227		AVI	Aviron
	0227		BA	Baxter (Inactive - use BAH)
	0227		BAH	Baxter Health Care
	0227		BAY	Bayer
	0227		BP	Berna (Inactive – use BPC)
	0227		BPC	Berna Products Corporation
	0227		BRR	Barr Labs, Inc.
	0227		CEN	Centeon L.L.C. (Inactive – use ZLB)
	0227		CHI	Chiron Corporation (Inactive – use NOV)
	0227		CMP	Celltech Medeva Pahm (Inactive – use NOV)
	0227		CNJ	Cangene Corporation
	0227		CON	Connaught (Inactive – use PMC)
	0227		CSL	bioCSL
	0227		DYN	DynPort Vaccine Company, LLC
	0227		EVN	Evans (Inactive – use NOV)
	0227		GRE	Greer
	0227		GRF	Grifols
	0227		IAG	Immuno International AG (Inactive – use BAH)
	0227		IDB	ID Biomedic
	0227		IM	Merieux (Inactive – Use PMC)
	0227		INT	Intercell Biomedical
	0227		IUS	Immuno-US
	0227		JPN	The Research foundation for Microbial Diseases of
				Osaka U.
	0227		KGC	Korea Green Cross
	0227		LED	Lederle (Inactive – use WAL)
	0227		MA	Massachusetts Public Health (Inactive-Use MBL)
	0227		MBL	Massachusetts Biologic Laboratories
	0227		MED	Medimmune PAY
	0227		MIL	Miles (Inactive – use BAY)
	0227		MIP	Emergent BioDefense Operations Lansing
	0227		MSD	Merck
	0227		NAB	North American Biologicals, Inc.
	0027		NAV	North American Vaccine (Inactive – use BAH)
	0227		NYB	New York Blood Center
	0227		NOV	Novartis
	0227		NVX	Novavax, Inc
	0227		OTC	Organon Teknika
	0227		ORT	Ortho-Clinical Diagnostics
	0227		PD	Parkdale Pharmaceuticals (formerly Parke Davis)
	0227		PAX	PaxVax
	0227		PFR	Pfizer, Inc.
	0227		PMC	Sanofi Pasteur Inc. (Pasteur Merieux Connaught) Aventis Pasteur Inc. (formerly Pasteur Merieux Connaught) merged with and into Sanofi.
	0227		PRX	Praxis Biologics (Inactive – use WAL)

Туре	Table	Name	Value	Description	
	0227		PSC	Protein Sciences Corporation	on
	0227		PWJ	Powderject Pharmaceutical	
	0227		SCL	Sclavo	
	0227		SEQ	Segirus	
	0227		SOL	Solvay Pharmaceuticals	
	0227		SKB	GlaxoSmithKline	
	0227		SI	Swiss Serum and Vaccine I	nst (Inactive – use BPC)
	0227		TAL	Talecris Biotherapeutics (in	· ,
	0227		USA	United States Army Medica	
	0227		VXG	VaxGen	
	0227		WA	Wyeth-Ayerst (Inactive – u	SE WAL)
	0227		WAL	Wyeth-Ayerst (Inactive – u	
	0227		ZLB	ZLB Behring (includes Aver	
	0221		ZLD	Pharmaceutical Co)	ilis belling and Amou
	0227		OTH	Other	
	0227		UNK	Unknown manufacturer	
User	0289	County/parish (Nebraska & some surrounding counties)			
	0289	Nebraska Counties	NE001	Nebraska	Adams
	0289		NE003	Nebraska	Antelope
	0289		NE005	Nebraska	Arthur
	0289		NE007	Nebraska	Banner
	0289		NE009	Nebraska	Blaine
	0289		NE011	Nebraska	Boone
	0289		NE013	Nebraska	Box Butte
	0289		NE015	Nebraska	Boyd
	0289		NE017	Nebraska	Brown
	0289		NE019	Nebraska	Buffalo
	0289		NE021	Nebraska	Burt
	0289		NE023	Nebraska	Butler
	0289		NE025	Nebraska	Cass
	0289		NE027	Nebraska	Cedar
	0289		NE029	Nebraska	Chase
	0289		NE031	Nebraska	Cherry
	0289		NE033	Nebraska	Cheyenne
	0289		NE035	Nebraska	Clay
	0289		NE037	Nebraska	Colfax
	0289		NE039	Nebraska	Cuming
	0289		NE041	Nebraska	Custer
	0289		NE043	Nebraska	Dakota
	0289		NE045	Nebraska	Dawes
	0289		NE047	Nebraska	Dawson
	0289		NE049	Nebraska	Deuel
			NE051	Nebraska	Dixon
	0289 0289		NE053	Nebraska	Dodge
			NE055	Nebraska	Douglas
	0289		NE057	Nebraska	Dundy
	0289		NE057	Nebraska	Fillmore
	0289		NE059 NE061	Nebraska	Franklin
	0289		NE063	Nebraska	
	0289			Nebraska	Frontier
	0289		NE065	Nebraska	Furnas
	0289		NE067		Gage
	0289		NE069	Nebraska	Garden
	0289		NE071	Nebraska	Garfield

Туре	Table	Name	Value	Description	
. 7 -	0289		NE073	Nebraska	Gosper
	0289		NE075	Nebraska	Grant
	0289		NE077	Nebraska	Greeley
	0289		NE079	Nebraska	Hall
	0289		NE081	Nebraska	Hamilton
	0289		NE083	Nebraska	Harlan
	0289		NE085	Nebraska	Hayes
			NE087	Nebraska	Hitchcock
	0289		NE089	Nebraska	Holt
	0289		NE091	Nebraska	Hooker
	0289			Nebraska	
	0289		NE093	Nebraska	Howard
	0289		NE095	Nebraska	Jefferson
	0289		NE097		Johnson
	0289		NE099	Nebraska	Kearney
	0289		NE101	Nebraska	Keith
	0289		NE103	Nebraska	Keya Paha
	0289		NE105	Nebraska	Kimball
	0289		NE107	Nebraska	Knox
	0289		NE109	Nebraska	Lancaster
	0289		NE111	Nebraska	Lincoln
	0289		NE113	Nebraska	Logan
	0289		NE115	Nebraska	Loup
	0289		NE117	Nebraska	McPherson
	0289		NE119	Nebraska	Madison
	0289		NE121	Nebraska	Merrick
	0289		NE123	Nebraska	Morrill
	0289		NE125	Nebraska	Nance
	0289		NE127	Nebraska	Nemaha
	0289		NE129	Nebraska	Nuckolls
	0289		NE131	Nebraska	Otoe
	0289		NE133	Nebraska	Pawnee
	0289		NE135	Nebraska	Perkins
	0289		NE137	Nebraska	Phelps
	0289		NE139	Nebraska	Pierce
	0289			Nebraska	
	0289		NE141	Nebraska	Platte
			NE143		Polk
	0289		NE145	Nebraska	Red Willow
	0289		NE147	Nebraska	Richardson
	0289		NE149	Nebraska	Rock
	0289		NE151	Nebraska	Saline
	0289		NE153	Nebraska	Sarpy
	0289		NE155	Nebraska	Saunders
	0289		NE157	Nebraska	Scotts Bluff
	0289		NE159	Nebraska	Seward
	0289		NE161	Nebraska	Sheridan
	0289		NE163	Nebraska	Sherman
	0289		NE165	Nebraska	Sioux
	0289		NE167	Nebraska	Stanton
	0289		NE169	Nebraska	Thayer
	0289		NE171	Nebraska	Thomas
	0289		NE173	Nebraska	Thurston
	0289		NE175	Nebraska	Valley
			NE177	Nebraska	Washington
	0289		NE177	Nebraska	Wayne
	0289			Nebraska	-
	0289		NE181	INEDIASKA	Webster

Туре	Table	Name	Value	Description	
7,	0289		NE183	Nebraska	Wheeler
	0289		NE185	Nebraska	York
	0289		CO075	Colorado	Logan
	0289		CO095	Colorado	Phillips
	0289		CO115	Colorado	Sedgwick
	0289		CO123	Colorado	Weld
	0289		CO125	Colorado	Yuma
	0289		IA071	Iowa	Fremont
	0289		IA085	Iowa	Harrison
	0289		IA129	Iowa	Mills
	0289		IA133	Iowa	Monona
	0289		IA149	Iowa	Plymouth
	0289			Iowa	Pottawattamie
	0289		IA155	Iowa	
	0289		IA193 KS013	Kansas	Woodbury
	0289			Kansas	Brown
	0289		KS023	Kansas	Cheyenne
	0289		KS039	Kansas	Decatur
	0289		KS089	Kansas	Jewell
	0289		KS117	Kansas	Marshall
	0289		KS123	Kansas	Mitchell
			KS131		Nemaha
	0289		KS137	Kansas	Norton
	0289		KS147	Kansas	Phillips
	0289		KS153	Kansas	Rawlins
	0289		KS157	Kansas	Republic
	0289		KS183	Kansas	Smith
	0289		KS201	Kansas	Washington
	0289		MO005	Missouri	Atchison
	0289		MO087	Missouri	Holt
	0289		SD007	South Dakota	Bennett
	0289		SD009	South Dakota	Bon Homme
	0289		SD023	South Dakota	Charles Mix
	0289		SD027	South Dakota	Clay
	0289		SD047	South Dakota	Fall River
	0289		SD053	South Dakota	Gregory
	0289		SD099	South Dakota	Minnehaha
	0289		SD113	South Dakota	Shannon
	0289		SD121	South Dakota	Todd
	0289		SD123	South Dakota	Tripp
	0289		SD135	South Dakota	Yankton
	0289		WY015	Wyoming	Goshen
	0289		WY021	Wyoming	Laramie
	0289		WY025	Wyoming	Natrona
	0289		WY027	Wyoming	Niobrara
	0289		WY031	Wyoming	Platte
HL7	0322	Completion status	**1001	, -	1 Idilo
. 1 /	0322	Completion status	СР	Complete	
	0322		RE	Refused	
	0322		NA DA	Not administered	
–	0322	<u> </u>	PA	Partially administered	
HL7	0323	Action code			
	0323		A	Add	
	0323		D	Delete	
	0323		U	Update	
HL7	0354	Message Structure			
	0354		ACK	ACK for all Trigger Eve	ents

Туре	Table	Name	Value	Description
71	0354		QBP_Q11	QBP for Q11 Trigger Event
	0354		RSP_K11	RSP for K11 Trigger Event
	0354		VXU V04	VXU for V04 Trigger Event
HL7	0357	Message Error Condition Codes		33.2.2.0.0
	0357	Error Status Codes	100	Segment sequence error
	0357	21101 0141440 00440	101	Required field missing
	0357		102	Data type error
	0357		103	Table value not found
	0357	Rejection Status Codes	200	Unsupported message type
	0357	rtojoston status souss	201	Unsupported event type
	0357		202	Unsupported processing ID
	0357		203	Unsupported version ID
	0357	Status Code	207	Application internal error
User	0363	Assigning Authority		, approximation and one
	0363		AKA	Alaska
	0363		ALA	Alabama
	0363		ARA	Arkansas
	0363		ASA	American Samoa
	0363		AZA	Arizona
	0363		BAA	New York City
	0363		CAA	California
	0363		CHA	Chicago
	0363		COA	Colorado
	0363		СТА	Connecticut
	0363		DCA	District of Columbia
	0363		DEA	Delaware
	0363		FLA	Florida
	0363		FMA	Fed States Micro
	0363		GAA	Georgia
	0363		GUA	Guam
	0363		HIA	Hawaii
	0363		IAA	Iowa
	0363		IDA	Idaho
	0363		ILA	Illinois
	0363		INA	Indiana
	0363		KSA	Kansas
	0363		KYA	Kentucky
	0363		LAA	Louisiana
	0363		MAA	Massachusetts
	0363		MDA	Maryland
	0363		MEA	Maine
	0363		MHA	Rep Mars Islands
	0363		MIA	Michigan
	0363		MNA	Minnesota
	0363		MOA	Missouri
	0363		MPA	No. Mariana Islands
	0363		MSA	Mississippi
	0363		MTA	Montana
	0363		NCA	North Carolina
	0363		NDA	North Dakota
	0363		NEA	Nebraska
	0363		NHA	
	0363		NJA	New Hampshire New Jersey
	0363		NMA	New Mexico

Туре	Table	Name	Value	Description
71	0363		NVA	Nevada
	0363		NYA	New York State
	0363		OHA	Ohio
	0363		OKA	Oklahoma
	0363		ORA	Oregon
	0363		PAA	Pennsylvania
	0363		PHA	Philadelphia
	0363		PRA	Puerto Rico
	0363		RIA	Rhode Island
	0363		RPA	
	0363			Republic Palau
			SCA	South Carolina
	0363		SDA	South Dakota
	0363		THA	San Antonio
	0363		THA	Houston
	0363		TNA	Tennessee
	0363		TXA	Texas
	0363		UTA	Utah
	0363		VAA	Virginia
	0363		VIA	Virgin Islands
	0363		VTA	Vermont
	0363		WAA	Washington
	0363		WIA	Wisconsin
	0363		WVA	West Virginia
	0363		WYA	Wyoming
User	0441	Immunization registry status		
	0441		A	Active
	0441		I	Inactive - unspecified
	0441		L	Inactive – Lost to follow-up (cannot contact)
	0441		M	Inactive – Moved or gone elsewhere (transferred)
	0441		P	Inactive – Permanently inactive (do not reactivate or add
			1.1	new entries to this record
	0441	E G '4	U	Unknown
HL7	0516	Error Severity		Information
	0516		I I	Information
	0516		W	Warning
	0516		E	Error
User	0533	Application Error Code		
	0533		1	Illogical Date error
	0533		2	Invalid Date
	0533		3	Illogical Value error
	0533		4	Invalid value
	0533		5	Table value not found
	0533		6	Required observation missing
NIP	NIP001	Immunization Information Source		
	NIP001		00	New Immunization Record
	NIP001		01	Historical Information
	NIP001		02	Historical information – from other provider
	NIP001		03	Historical information – from parent's written record
	NIP001		04	Historical information – from parent's recall
	NIP001		05	Historical information – from other registry
	NIP001		06	Historical information – from birth certificate
		<u> </u>		
	NIP001		07	Historical information – from school record
	NIP001 NIP001		08	Historical information – from school record Historical information – from public agency
			07	Historical information – from school record

Туре	Table	Name	Value	Description
	NIP002		00	Parental decision
	NIP002		01	Religious exemption
	NIP002		02	Other (must add text component of the CE field with
				description)
	NIP002		03	Patient decision
NIP	NIP004	Contraindications , Precautions		Note: This table has been replaced by separate tables for contraindications, indications, reactions, and immunities
	NIP004		MA	Physician documented exemption due to medical
	NIP004		MB	reasons for DTP/aP vaccine group Physician documented exemption due to medical
				reasons for Pediatric DT vaccine
	NIP004		MC	Physician documented exemption due to medical reasons for Hepatitis A vaccine group
	NIP004		MD	Physician documented exemption due to medical
	NIP004		ME	reasons for Hepatitis B vaccine group
	NIP004		IVIE	Physician documented exemption due to medical reasons for Hib vaccine group
	NIP004		MF	Physician documented exemption due to medical
	NIP004		MG	reasons for MMR vaccine group Physician documented exemption due to medical
	1411 004		WIG	reasons for Meningococcal vaccine group
	NIP004		МН	Physician documented exemption due to medical reasons for Pneumococcal vaccine group
	NIP004		MI	Physician documented exemption due to medical
				reasons for Polio vaccine group
	NIP004		MJ	Physician documented exemption due to medical reasons for Rotavirus vaccine group
	NIP004		MK	Physician documented exemption due to medical reasons for Adult Td vaccine group
	NIP004		ML	Physician documented exemption due to medical reasons for Varicella vaccine group
	NIP004		RABEXP	Client has been exposed to Rabies
	NIP004		P1	Refusal of DT
	NIP004		P2	Refusal of DTaP
	NIP004		P3	Refusal of HepB
	NIP004		P4	Refusal of Hib
	NIP004		P5	Refusal of MMR
	NIP004		P6	Refusal of Pneumococcal
	NIP004		P7	Refusal of Polio
	NIP004		P8	Refusal of TD
	NIP004		P9	Refusal of Varicella
	NIP004		РВ	Refusal of HepA
	NIP004		PC	Refusal of Influenza
	NIP004		PD	Refusal of Meningococcal
	NIP004		PE	Refusal of Rotavirus
	NIP004		PF	Refusal of HPV
	NIP004		PG	Refusal of Pertussis
	NIP004		PJ	Refusal of Novel Influenza-09
	NIP004		PK	Refusal of Zoster
	NIP004		PM	Refusal of MeningB
	NIP004		PS	Refusal of Smallpox
	NIP004		PT	Refusal of Tdap
	NIP004		R1	Clinician has decided to repeat the DTAP series
	NIP004		R2	Clinician has decided to repeat the Hep B series
	NIP004		R3	Clinician has decided to repeat the HIB series
	NIP004		R4	Clinician has decided to repeat the Polio series
	NIP004		R5	Clinician has decided to repeat the MMR series
	NIP004		R6	Clinician has decided to repeat the Pneumococcal series
	NIP004		R7	Clinician has decided to repeat the Varicella series
	NIP004		R8	Clinician has decided to repeat the Meningococcal series
	NIP004		R9	Clinician has decided to repeat the HepA series

Туре	Table	Name	Value	Description
	NIP004		RX	Clinician has decided to repeat the Influenza series
NIP	NIP005	Event Consequence		
	NIP005		D	Patient Died
	NIP005		L	Life threatening illness
	NIP005		E	Required emergency room/doctor visit
	NIP005		Н	Required hospitalization
	NIP005		Р	Resulted in prolongation of hospitalization
	NIP005		J	Resulted in permanent disability
NIP	NIP006	Patient Registry Status		
	NIP006		Α	Active
	NIP006		N	Inactive
	NIP006		М	Moved or Gone Elsewhere
				(In NESIIS used for Moved out of State)
	NIP006		Р	Permanently inactive - deceased
NIP	NIP008	Vaccine Funding Code	PVF	Private funds
	NIP008		PBF	Public funds

	V2.5.1 Coding System	V2.5.1 Value	V2.3.1 NIP004 Value	Description
HL7	0396	Vaccine Contraindications		
	CDCPHINVS	VXC18	03	Allergy to baker's yeast (anaphylactic)
	SCT	91930004	04	Allergy to egg ingestion (anaphylactic)
	SCT	294847001	05	Allergy to gelatin (anaphylactic)
	SCT	300916003	LA	Allergy to latex
	SCT	294468006	06	Allergy to neomycin (anaphylactic) - MMR IPV VZV
	SCT	294466005	07	Allergy to streptomycin (anaphylactic)
	CDCPHINVS VXC19	VXC19	08	Allergy to thimerosal (anaphylactic)
	CDCPHINVS	VXC20	09	Allergy to previous dose of this vaccine or to any of its unlisted vaccine components (anaphylactic)
	NIP004	14	14	Current diarrhea, moderate to severe
	CDCPHINVS	VXC22	15	Encephalopathy within 7 days of previous dose of DTP
	CDCPHINVS	VXC23	16	Current fever with moderate-to-severe illness
	NIP004	18	18	Gullain-Barre syndrome (GBS) within 6 weeks of previous dose of DTP/DTaP
	CDCPHINVS	VXC24	21	Current acute illness, moderate to severe (with or without fever) (e.g. diarrhea, otitis media, vomiting)
	CDCPHINVS	27624003	22	Chronic illness (e.g. chronic gastrointestinal disease)
	NIP004	23	23	Immune globulin (IG) administration, recent or simultaneous
	NIP004	34	34	Immunodeficiency (family history)
	NIP004	35	35	Immunodeficiency (household contact)
	CDCPHINVS	VXC27	36	Immunodeficiency (hematologic and solid tumors, congenital immunodeficiency, long-term immunosuppressive therapy, including steroids) (in recipient)
	CDCPHINVS	VXC26	37	Neurologic disorders, underlying (including seizure disorders, cerebral palsy, and developmental delay)
	NIP004	38	38	Otitis media (ear infection) moderate to severe (with or without fever)

	V2.5.1 Coding			
	System	V2.5.1 Value	V2.3.1 NIP004 Value	Description
	SCT	77386006	39	Pregnancy (in recipient)
	SCT	302215000	40	Thrombocytopenia
	SCT	161461006	41	Thrombocytopenic purpura (history)
	CDCPHINVS	VXC21	61	Previous history of intussusception
	CDCPHINVS		62	History of Arthus hypersensitivity reaction to a tetanus-
	CDCFTIIIVS	VXC25	02	containing vaccine administered < 10 yrs previously
	NIP004	СР	СР	Pertussis contraindication and precautions
	NIP004	СТ	СТ	Tetanus contraindication – allergic reaction
HL7	0396	Evidence of Immunity		
	SCT	397428000	24	History/immunity: diphtheria
	SCT	91428005	25	History/immunity: HIB
	SCT	40468003	HEPA_I	History/immunity: Hepatitis A
	SCT	66071002	26	History/immunity: Hepatitis B
	SCT	14189004	27	History/immunity: measles
	SCT	36989005	28	History/immunity: mumps
	SCT	27836007	29	History/immunity: pertussis
	SCT	398102009	30	History/immunity: poliovirus
		36653000	31	History/immunity: rubella
	SCT	76902006	32	History/immunity: tetanus
	SCT		33	History/immunity: varicella
	SCT	38907003	57	History/immunity: varicella History/immunity: anthrax
	SCT	409498004		
	SCT	240532009	80	History/immunity: HPV
	SCT	6142004	60	History/immunity: influenza
	SCT	52947006	59	History/immunity: Japanese encephalitis
	SCT	23511006	54	History/immunity: meningococcal
	SCT	16814004	81	History/immunity: pneumococcal
	SCT	14168008	75	History/immunity: rabies
	SCT	18624000	53	History/immunity: rotavirus
	SCT	4834000	58	History/immunity: typhoid
	SCT	111852003	50	History/immunity: vaccinia
	SCT	16541001	51	History/immunity: yellow fever
HL7	0396	Serological Evidence of		
		Immunity		
	SCT	278971009	HEPA_I	History/immunity: Hepatitis A
	SCT	271511000	26	History/immunity: Hepatitis B
	SCT	371111005	27	History/immunity: measles
	SCT	341112003	28	History/immunity: mumps
	SCT	278968001	31	History/immunity: rubella
	SCT	371113008	33	History/immunity: varicella
HL7	0396	Reaction Codes		
	NESIIS001	ERVISIT	ERVISIT	Required emergency room/doctor visit
	SCT	39579001	ANAPH	Anaphylaxis
	CDPHINVS	VXC10	HYPOTON	Hypotonic-hyporesponsive collapse within 48 hours of immunization
	CDPHINVS	VXC11	SEIZURE	Seizure occurring within 3 days
	CDPHINVS	VXC9	CRYING	Persistent crying lasting >= 3 hours within 48 hours of immunization
	CDPHINVS	VXC12	FEVER105	Temperature >= 105 (40.5 C) within 48 hours of
				immunization

Type	Table	Name	Value	Description
NESIIS	WVGC	Vaccine Group Code (WVGC)		
	WVGC		Adeno	Adeno

Type	Table	Name	Value	Description
	WVGC		Anthrax	Anthrax
	WVGC		BCG	BCG
	WVGC		Cholera	Cholera
	WVGC		Diphtheria	Diphtheria Antitoxin
	WVGC		DTP/aP	Diphtheria, Tetanus, Acellular Pertussis (< 7 years old)
	WVGC		Encephalitis	Encephalitis
	WVGC		Flu H1N1-09	Novel Influenza-H1N1-09
	WVGC		НерА	Hepatitis A
	WVGC		НерВ	Hepatitis B
	WVGC		Hib	Hib
	WVGC		HPV	Human Papilloma Virus
	WVGC		lg	Ig
	WVGC		Influenza	Influenza
	WVGC		Lyme	Lyme
	WVGC		Measles	Measles Virus Vaccine
	WVGC		MMR	Measles, Mumps, Rubella
	WVGC		Meningo	Meningitis
	WVGC		MeningB	Meningococcal B
	WVGC		Mumps	Mumps Virus Vaccine
	WVGC		Pertussis	Pertussis
	WVGC		Plague	Plague
	WVGC		Pneumococcal	Pneumonia Conjugate
	WVGC		Pneumo-Poly	Pneumonia Polysaccharide
	WVGC		Polio	Poliomyelitis
	WVGC		Rabies	Rabies
	WVGC		Rotavirus	Rotavirus
	WVGC		Rubella	Rubella Virus Vaccine
	WVGC		Tetanus	Tetanus
	WVGC		Td	Tetanus Diphtheria
	WVGC		Tdap	Diphtheria, Tetanus, Acellular Pertussis (=> 7 years old)
	WVGC		Typhoid	Typhoid
	WVGC		Smallpox	Vaccinia
	WVGC		Varicella	Varicella
	WVGC		Yellow Fever	Yellow Fever
	WVGC		Zoster	Zoster
	***************************************		200101	20001
NESIIS	WVTN	Vaccine Trade Name (WVTN)		
	WVTN		Acel-Imune	DTaP
	WVTN		ActHib	Hib-PRP-T
	WVTN		Adacel	TdaP > 7 years
	WVTN		Adeno T4	Adeno T4
	WVTN		Adeno T7	Adeno T7
	WVTN		Adenovirus types 4 and 7	Adenovirus types 4 and 7
	WVTN		Afluria	Influenza, seasonal, injectable
	WVTN		Afluria Quad, P-free	Influenza, inject, quadrivalent, p-free
			Afluria Quadrivalent	Influenza, inject, quadrivalent
	WVTN		Afluria, P-free	Influenza, seasonal, P-free
	WVTN		Agriflu, P-free	Influenza, seasonal, P-free
	WVTN		Biothrax	Anthrax
	WVTN			Measles
	WVTN		Attenuvax	
	WVTN		BabyBIG	Botulism
	WVTN		BayTet	Tig
	WVTN		BCG-Cancer	BCG-BC
	WVTN		BCG-TB	BCG-TB

Type	Table	Name	Value	Description
	WVTN		BEXSERO	Meningococcal B, OMV
	WVTN		Biavax II	Rubella-Mumps
	WVTN		BIG	Botulism
	WVTN		Boostrix	TdaP > 7 years
	WVTN		Botulinum-antitoxin	Botulinum-antitoxin
	WVTN		Botulism	Botulism
	WVTN		Certiva	DTaP
	WVTN		Cervarix	HPV, Bivalent
	WVTN		Cholera-I	Cholera-Inject
	WVTN		Cholera-O	Cholera-Oral
	WVTN		CMV-IgIV	CMV-lgIV
	WVTN		Comvax	HepB-Hib
	WVTN		DAPTACEL	DTaP,5 pertussis antigens
	WVTN		DECAVAC	Td (adult) preservative free
			Diphtheria	Diphtheria
	WVTN		Diphtheria-antitoxin	Diphtheria-antitoxin
	WVTN		Dryvax	Smallpox
	WVTN		DT	DT-Peds
	WVTN		DTP	DTP
	WVTN			
	WVTN		Engerix-B Adult	HepB-Adult
	WVTN		Engerix-B dialysis	HepB-Dialysis 4 dose
	WVTN		Engerix-B Peds	HepB-Peds
	WVTN		Flebogamma	IgIV
	WVTN		Flu-Imune	Influenza, seasonal, injectable
	WVTN		Flu-Shield	Influenza, seasonal, injectable
	WVTN		Fluad	Influenza, trivalent, adjuvanted
	WVTN		Fluarix, P-free	Influenza, seasonal, P-free
	WVTN		Fluarix Quadrivalent	Influenza, inject, quadrivalent, p-free
	WVTN		Flublok	Influenza, recombinant, inject, p-free
	WVTN		Flucelvax	Influenza, injectable, MDCK, p-free
	WVTN		Flucelvax Quadrivalent	Influenza, inject, MDCK, quad, p-free
	WVTN		FluLaval	Influenza, seasonal, injectable
	WVTN		Flulaval, P-free	Influenza, seasonal, P-free
	WVTN		Flulaval Quadrivalent	Influenza, injectable, quadrivalent
	WVTN		Flulaval Quad, P-free	Influenza, inject, quadrivalent, p-free
	WVTN		FluMist	Influenza, seasonal, live, intranasal
	WVTN		FluMist Quadrivalent	Influenza, live, nasal, quadrivalent
	WVTN		Fluogen	Influenza, seasonal, injectable
	WVTN		Fluvirin	Influenza, seasonal, injectable
	WVTN		Fluvirin, P-free	Influenza, seasonal, P-free
	WVTN		Fluzone	Influenza, seasonal, injectable
	WVTN		Fluzone, P-free	Influenza, seasonal, P-free
	WVTN		Fluzone High-Dose P-free	Influenza, seasonal, High-Dose, P-free
			Fluzone Intraderm P-free	Influenza, seasonal, intradermal, P-free
	WVTN		Fluzone Quad, P-free	Influenza, inject, quadrivalent, p-free
	WVTN			Influenza, inject, quad, peds, p-free
	WVTN			Influenza, intradermal, quad, p-free
	WVTN		Fluzone Quadrivalent	Influenza, injectable, quadrivalent
	WVTN		Gardasil	l i
	WVTN			HPV, Quadrivalent
	WVTN		Gardasil 9	Human Papillomavirus 9-valent vaccine
	WVTN		H1N1 Flu-Mist	Novel Influenza-H1N1-09, nasal
	WVTN		H1N1 Afluria	Novel Influenza-H1N1-09
	WVTN		H1N1 Afluria, P-free	Novel Influenza-H1N1-09, preserve-free
	WVTN		H1N1 Fluvirin	Novel Influenza-H1N1-09
	WVTN		H1N1 Fluvirin, P-free	Novel Influenza-H1N1-09, preserve-free

Type	Table	Name	Value	Description
	WVTN		H1N1 Fluzone	Novel Influenza-H1N1-09
	WVTN		H1N1 Fluzone, P-free	Novel Influenza-H1N1-09, preserve-free
	WVTN		Havrix-Adult	HepA-Adult
	WVTN		Havrix-Peds 2 Dose	HepA-Ped 2 Dose
	WVTN		Havrix-Peds 3 Dose	HepA-Peds
	WVTN		HBIg	HBIg
	WVTN		Hib-TITER	Hib-HbOC
	WVTN		Hiberix	Hib-PRP-T
	WVTN		HyperRAB S/D	RIg-HT
	WVTN		lg	lg
	WVTN		IgIV	IgIV
	WVTN		Imogam Rabies - HT	RIg-HT
	WVTN		Imovax Rabies ID	Rabies-ID
	WVTN		Imovax Rabies IM	Rabies-IM
			Infanrix	DTaP
	WVTN		IPOL	Polio-Inject
	WVTN		Ixiaro	Japanese encephalitis-IM
	WVTN		JE-Vax	Japanese encephalitis-SC
	WVTN		Kinrix	DTaP-IPV
	WVTN		LYMErix	Lyme
	WVTN			
	WVTN		M-R-VAX	Measles-Rubella
	WVTN		Measles	Measles
	WVTN		Measles-Rubella (MERU)	Measles-Rubella
	WVTN		Menactra	Meningococcal (MCV4P)
	WVTN		Menhibrix	Meningococcal C/Y-Hib PRP
	WVTN		MENOMUNE	Meningococcal (MPSV4)
	WVTN		Menveo	Meningococcal (MCV4O)
	WVTN		Meruvax II	Rubella
	WVTN		MMR II	MMR
	WVTN		MMRV	MMRV
	WVTN		Mumps	Mumps
	WVTN		Mumps-Rubella (MURU)	Rubella-Mumps
	WVTN		Mumpsvax	Mumps
	WVTN		OmniHib	Hib-PRP-T
	WVTN		ORIMUNE	Polio-Oral
	WVTN		Pediarix	DTAP/Polio/Hep B
	WVTN		PedvaxHIB	Hib-OMP
	WVTN		Pentacel	DtaP-Hib-IPV
	WVTN		Pertussis	Pertussis
	WVTN		Plague	Plague
	WVTN		Pneumovax 23	Pneumococcal 23
	WVTN		PNU-IMUNE 23	Pneumococcal 23
	WVTN		Prevnar 7	Pneumo-Conjugate
			Prevnar 13	Pneumo-Conjugate 13
	WVTN		ProHIBit	Hib-PRP-D
	WVTN		Proquad	MMRV
	WVTN		Quadracel	DTaP-IPV
	WVTN		RabAvert	Rabies-IM
	WVTN		Recombivax Peds	HepB-Peds
	WVTN			
	WVTN		Recombivax-Adult	HepB-Adult
	WVTN		Recombivax-Dialysis	HepB-Dialysis 4 dose
	WVTN		Rho(D)Full	Rho(D)Full
	WVTN		Rho(D)IV	Rho(D)IV
	WVTN		Rho(D)Mini	Rho(D)Mini
	WVTN		RIg	RIg

Туре	Table	Name	Value	Description
	WVTN		RIg-HT	RIg-HT
	WVTN		RotaShield	Rotavirus, Tetravalent
	WVTN		RotaTeq	Rotavirus, Pentavalent
	WVTN		Rotarix	Rotavirus, monovalent
	WVTN		RSV-IgIM	RSV-IgIM
	WVTN		RSV-IgIV	RSV-IgIV
	WVTN		Rubella	Rubella
	WVTN		Td	Td (adult), absorbed
	WVTN		Td P-free	Td (adult) preservative free
	WVTN		TENIVAC	Td (adult) preservative free
	WVTN		Tetramune	DTP-Hib
	WVTN		TIg	Tig
	WVTN		TriHIBit	DTaP-Hib
	WVTN		Tripedia	DTaP
	WVTN		Trumenba	Meningococcal B, recombinant
	WVTN		TT	Tetanus
	WVTN		Twinrix	HepA-HepB Adult
	WVTN		Typhim Vi	Typhoid-ViCPs
	WVTN		Typhoid	Typhoid-HP
	WVTN		Typhoid-AKD	Typhoid-AKD
	WVTN		Vaccinia (smallpox), diluted	Vaccinia (smallpox), diluted
	WVTN		Vaccinia immune globulin VIG	Vaccinia immune globulin VIG
	WVTN		VAQTA-Adult	HepA-Adult
	WVTN		VAQTA-Peds 2 Dose	HepA-Ped 2 Dose
	WVTN		Varivax	Varicella
	WVTN		Vaxchora	Cholera, live attenuated
	WVTN		Vivotif	Typhoid-Oral
	WVTN		VZIg	VZIg
	WVTN		YF-VAX	Yellow Fever
	WVTN		Zostavax	Zoster (shingles), live

CPT Codes (WCPT) and CVX Codes (292)

CPT	CVX	Group	Vaccine	Trade Name	Description	MFG
90476	54	Adeno	Adenovirus, type 4	Adeno T4	Adenovirus type 4, live oral	WAL
90477	55		Adenovirus, type 7	Adeno T7	Adenovirus type 7, live oral	WAL
	143		Adenovirus type 4 and 7	Adenovirus types 4 and 7	Adenovirus, type 4 and type 7, live, oral	BRR
	82		Adeno, unspecified formulation		Adenovirus vaccine, unspecified formulation Used to be recorded as CVX 55, not recorded as CVX 82	
90581	24	Anthrax	Anthrax	Biothax	Anthrax	MIP
90585	19	BCG	BCG-TB	BCG-TB	Bacillus Calmette-Guerin TB	OTC
90586			BCG-BC	BCG-BC	Bacillus Calmette-Guerin bladder cancer	OTC
90728			BCG, unspecified formulation		BCG, unspecified formulation	
	173	Cholera	Cholera, BivWC		Cholera, BivWC	
90725			Cholera-Inject	Cholera-I	Cholera-Inject	
90625	174		Cholera, live attenuated	Vaxchora	Cholera, live attenuated	PAX
	26		Cholera, unspecified formulation		Cholera, unspecified formulation	
	172		Cholera, WC-rBS		Cholera, WC-rBS	
90719		Diphtheria	Diphtheria	Diphtheria	Diphtheria toxoid, intramuscular use	PD
90700	20	DTP/aP	DTaP	Acel-Imune	Diphtheria, tetanus, acellular	WAL
				Certiva	pertussis	BAH
				Infanrix		SKB
		1		Tripedia		PMC
90701	01		DTP	DTP	Diphtheria, tetanus, whole cell pertussis	PMC
90702	28	1	DT (pediatric)	DT	Diphtheria tetanus pediatric	PMC
90720	22	1	DTP-Hib	Tetramune	DTP – Hib combination	WAL
90721	50		DTaP-Hib	TriHIBit	DTaP-Hib combination	PMC
90723	110		DTaP-Hep B-IPV	Pediarix	DTaP-HepB-Polio combination	SKB
90698	120	1	DTaP-Hib-IPV	Pentacel	DTaP-Hib-IPV combination	PMC
90696	130		DTaP-IPV	Kinrix	DTaP-IPV combination	SKB
				Quadracel	DTaP-IPV combination	PMC
90700	106		DTAP, 5 pertussis antigens	DAPTACEL	Diphtheria, tetanus, acellular pertussis, 5 antigens	PMC
	107	j	DTaP, unspecified formulation		DTaP, unspecified formulation	
	102]	DTP-HIB-HepB		DTP-HIB-Hep B vaccine	
	132		DTaP-IPV-HIB-HEP B, historical		DTaP-IPV-HIB-HEP B, historical	
	170		DTAP/IPV/HIB - non-US		DTAP/IPV/HIB - non-US	
90664	125	Flu H1N1-09	Novel Influenza-H1N1-09, nasal	H1N1 Flu-Mist	Influenza virus vaccine, pandemic formulation, live, for intranasal use	MED
90666	126	1	Novel Influenza-H1N1-09,	H1N1 Afluria, P-free	Influenza virus vaccine,	CSL
			preserve-free	H1N1 Fluvirin, P-free	pandemic formulation, split-	SEQ
				H1N1 Fluzone, P-free	virus, preservative free, for intramuscular use	PMC
90668	127	1	Novel Influenza-H1N1-09	H1N1 Afluria	Influenza virus vaccine,	CSL
	,		TO S. IIII GOILLA TITTAT OU	H1N1 Fluvirin	pandemic formulation, split- virus, for intramuscular use	SEQ
				H1N1 Fluzone	1	PMC
90663	128	-	Novel Influenza-H1N1-09 all formulations	TITIVI FIUZUIIE	Influenza virus vaccine, pandemic formulation, H1N1	I Y IVIC
90630	166	Influenza	Influenza, intradermal, quad, p-free	Fluzone Quad Intradermal	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use	PMC
90653	168	1	Influenza, trivalent, adjuvanted	Fluad	Influenza, trivalent, adjuvanted	SEQ
90654	144	1	Influenza, seasonal, intradermal, P-free	Fluzone Intraderm P-free	Influenza, seasonal, intradermal, preservative free	PMC
90655	140	1	Influenza, seasonal, P-free	Fluvirin, P-free	Influenza, seasonal, injectable,	SEQ
22000	0			Fluzone, P-free	preservative free	PMC
1				Fluarix, P-free	†՝	SKB
				ITIUATIA, FILEE		
				Afluria, P-free	1	
				Afluria, P-free Agriflu, P-free	-	SEQ SEQ

CPT	CVX	Group	Vaccine	Trade Name	Description	MFG
90656				Fluvirin, P-free		SEQ
				Fluzone, P-free		PMC
				Fluarix, P-free		SKB
				Afluria, P-free		SEQ
				Agriflu, P-free		SEQ
00660	135		Influenza Lligh Doog D from	Flulaval, P-free	Influenza acceptal high door	IDB PMC
90662	135		Influenza High-Dose, P-free	Fluzone High-Dose P-free	Influenza, seasonal, high dose, preservative-free	PIVIC
90657	141		Influenza, seasonal, injectable	Flu-Immune	Influenza, seasonal, injectable	WAL
				FluLaval		IDB
				Flu-Shield		WAL
				Fluzone		PMC
				Afluria		SEQ
				Fluvirin		SEQ
00050				Fluogen	-	PD
90658				Flu-Immune FluLaval	-	WAL SKB
				Flu-Shield	1	WAL
				Fluzone		PMC
				Afluria		SEQ
				Fluvirin	1	SEQ
				Fluogen	1	PD
90660	111		Influenza, live, intranasal	FluMist	Seasonal influenza virus	WAL
					vaccine, live, attenuated, for	
00050	4.0		In the common NATION IN		intranasal use	
90659	16		Influenza, Whole virus	Flucelyey	Seasonal influenza whole virus	CEC.
90661	153		Influenza, injectable, MDCK, p-free	Flucelvax	Influenza, injectable, MDCK, p-free	SEQ
90672	149		Influenza, live, nasal,	FluMist Quadrivalent	Influenza virus vaccine,	MED
30072	140		quadrivalent	Trainist Quadrivalent	quadrivalent, live, for intranasal	IVILD
					use	
90673	155		Influenza, recombinant, inject,	Flublok	Influenza recombinant,	PSC
			p-free		injectable, preservative free	
90674	171		Influenza, inject, MDCK, quad,	Flucelvax Quadrivalent	Influenza, injectable, Madin	SEQ
			p-free		Darby Canine Kidney,	
90685	161		Influenza, inject, quad, peds, p-	Fluzona Quad Pade P-frae	preservative free, quadrivalent Influenza virus vaccine,	PMC
30000	101		free	Tuzone Quad reas, r nec	quadrivalent, split virus,	i ivio
					preservative free, when	
					administered to children 6-35	
					months of age, for intramuscular	
					use	
90686	150		Influenza, inject, quadrivalent,	Afluria Quad, P-free	Influenza virus vaccine,	SEQ
			p-free	Fluarix Quadrivalent	quadrivalent, split virus, preservative free, when	SKB
					administered to individuals 3	
				Flulaval Quad, P-free	years of age and older, for	IDB
				,	intramuscular use	
				Fluzone Quad, P-free		PMC
90687	158		Influenza, injectable,	Afluria Quadrivalent	Influenza virus vaccine,	SEQ
00007	.00		quadrivalent	Flulaval Quadrivalent	quadrivalent, split virus, when	IDB
			-	Fluzone Quadrivalent	administered to children 6-35	PMC
					months of age, for intramuscular	
0.5				10.10.11	use	0=-
90688				Afluria Quadrivalent	Influenza virus vaccine,	SEQ
					quadrivalent, split virus, when administered to individuals 3	
				Flulaval Quadrivalent	years of age and older, for	IDB
					intramuscular use.	
				Fluzone Quadrivalent	1	PMC
	151		Influenza, nasal, unspecified		Influenza, nasal, unspecified	
			formulation		formulation	
90724	88		Influenza, unspecified		Seasonal influenza, unspecified	
			formulation		formulation	
					CVX 15 has been retired by the	
					CDC and replaced by CVX 140	
					and 141	
1						

CPT	CVX	Group	Vaccine	Trade Name	Description	MFG
					If CVX 15 is sent it will be	
					recorded as CVX 88 Influenza,	
00000		НерА	Llan A. andruk	Lieuwise Askult	unspecified formulation	CIAD
90632	52	нера	Hep A, adult	Havrix-Adult	Hepatitis A adult	SKB
90633	83	_	Hep A, ped/adol, 2 dose	VAQTA-Adult Havrix-Peds 2 Dose	Hepatitis A pediatric/adolescent	MSD SKB
90033	03		Hep A, ped/adol, 2 dose	VAQTA-Peds 2 Dose	2 dose	MSD
90634	84	-	Hep A, ped/adol, 3 dose	Havrix-Peds 3 Dose	Hepatitis A pediatric/adolescent	SKB
30034	04		Tiep A, ped/adoi, 3 dose	l laviix-i eus 3 dose	3 dose	MSD
90636	104	-	HepA-HepB Adult	Twinrix	Hepatitis A & Hepatitis B adult	SKB
90730	85		Hep A, unspecified formulation	I WIIIIX	Hep A, unspecified formulation	OND
00100	31	1	Hep A-peds, unspecified		Recorded as CVX 85	
	0.		formulation		110001404 40 0 77 00	
	169		Hep A, live attenuated			
90636	104	НерВ	HepA-HepB Adult	Twinrix	Hepatitis A & Hepatitis B adult	SKB
90723	110	1 '	DTaP-Hep B-IPV	Pediarix	DTAP-HepB-Polio combination	SKB
90731	45		Hep B, unspecified formulation		Hep B, unspecified formulation	
90739	43		Hep B, adult		Hepatitis B, adult dosage (2	
					dose schedule), for	
					intramuscular use	
90740	44		Hep B, dialysis		Hep B, dialysis	
90743	43		Hep B, adult	Recombivax-Adult	Hepatitis B vaccine, adolescent	MSD
					(2 dose schedule), for	
		1			intramuscular use	
90744	80		Hep B, adolescent or pediatric	Recombivax-Peds	Hepatitis B pediatric/adolescent	MSD
				Engerix-B Peds	.5ml	SKB
90745	42		Hep B, adolescent/high risk		Hep B, adolescent/high risk	
00740	40	_	infant	December Adult	infant	MOD
90746	43		Hep B, adult	Recombivax-Adult	Hepatitis B adult dose 1ml	MSD
00747	4.4		Han D. dialysis 4 dags	Engerix-B Adult	Hanatitia D Dialysia 4 daga	SKB MSD
90747	44		Hep B, dialysis 4 dose	Recombivax-Dialysis	Hepatitis B Dialysis 4 dose	SKB
90748	51	_	Lib Llop D	Engerix-B dialysis	Lland Llib Combination	MSD
90746		-	Hib-Hep B DTaP-IPV-HIB-HEP B,	Comvax	HepB-Hib Combination DTaP-IPV-HIB-HEP B, historical	INIOD
	132		historical		DTAP-IPV-HIB-HEP B, HISTORICAL	
90645	47	Hib	Hib (HbOC)	HibTITER	Haemophilus influenza b HbOC	WAL
90646	46	+	Hib (PRP-D)	ProHIBit	4 dose Haemophilus influenza b PRP-D	PMC
90040	40		TIID (FKF-D)	FIOLIDIC	booster	FIVIC
90647	49	1	Hib (PRP-OMP)	PedvaxHIB	Haemophilus influenza b OMP 3 dose	MSD
90648	48	+	Hib (PRP-T)	OmniHib		PMC
90040	40		TIID (FKF-T)	ActHib	4 dose	PMC
				Hiberix	- dose	SKB
90720	22	+	DTP-Hib	Tetramune	DTP – Hib combination	WAL
90721	50		DTaP-Hib	TriHIBit	DTaP-Hib combination	PMC
90737	17	-	Hib, unspecified formulation	THIRDIC	Hib, unspecified formulation	1 IVIO
90748	51	1	Hib-Hep B	Comvax	HepB-Hib combination	MSD
90698	120	1	DTaP-Hib-IPV	Pentacel	DTaP-Hib-IPV combination	PMC
90644	148	1	Meningococcal C/Y-Hib PRP	Menhibrix	Meningococcal C/Y-Hib PRP	SKB
	132	1	DTaP-IPV-HIB-HEP B,		DTaP-IPV-HIB-HEP B, historical	
			historical		2,	
	170	1	DTAP/IPV/HIB - non-US		DTAP/IPV/HIB - non-US	
90649	62	HPV	HPV, Quadrivalent	Gardasil	Human Papilloma Virus,	MSD
					quadrivalent	
90650	118	<u></u>	HPV, Bivalent	Cervarix	Human Papilloma Virus, bivalent	SKB
	137		HPV, unspecified formulation		HPV, unspecified formulation	
90651	165		HPV9	Gardasil 9	Human Papillomavirus 9-valent	MSD
					vaccine	
	160	H5N1 flu	Influenza A (H5N1),	Influenza A (H5N1),	Influenza A (H5N1),	SKB
	400	4	ADJUVANTED-2013	ADJUVANTED-2013	ADJUVANTED-2013	IDE
00001	123	la.	Influenza, H5N1-1203	l.	Influenza, H5N1-1203	IDB
90281	86	lg	lg	lg	Ig human	
90283	87		IgIV	IgIV	Ig IV human	
00007	07	4	Dotulinum ontitavia	Flebogamma	Dotulinum antitavia assisa	
90287	27	4	Botulinum-antitoxin	Botulinum-antitoxin	Botulinum antitoxin equine	
90288			Botulism	BabyBIG	Botulism Immune Globulin	
	1			Botulism BIG		
		•	•	טוטו	i i	1
90201	20		CM\/-IgI\/		Cytomegalovirus la IV human	
90291	29	- -	CMV-lgIV	CMV-IgIV Ig	Cytomegalovirus Ig IV human immune globulin, unspecified	

CPT	CVX	Group	Vaccine	Trade Name	Description	MFG
90296	12	O. Gup	Diphtheria-antitoxin	Diphtheria-antitoxin	Diphtheria antitoxin, equine, any	0
00200			Diprimieria arimezari		route	
90371	30		HBlg	HBIg	Hepatitis B Ig human	
90375	34		RIg	Rig	Rabies Ig human	
90376	34		RIg-HT	HyperRAB S/D	Rabies Ig heat treated human	GRF
				Imogam Rabies - HT	7	PMC
				RIg-HT	7	
90378	93		RSV-IgIM	Synagis	Respiratory syncytial virus Ig	
90379	71		RSV-IgIV	RSV-IgIV	Respiratory syncytial virus Ig IV	
90384			Rho(D)Full	Rho(D)Full	Rho(D)Ig RhIG human full-dose	ORT
90385			Rho(D)Mini	Rho(D)Mini	Rho(D)Ig RhIG human mini-dose	
90386			Rho(D)IV	Rho(D)IV	Rho(D)Ig RhIG human IV	CSL
90389	13		TiG	BayTet	Tetanus Ig human	
				TiG	7	
	157		Rho(D) IG IM		Rho(D) Immune globulin - IM	
	156		Rho(D) IG		Rho(D) Immune globulin – IV or IM	
	159		Rho(D), unspecified		Rho(D), unspecified formulation	
00000	70	4	formulation	Magainia In	Vaccinia la burnera	
90393	79	4	Vaccinia immune globulin	Vaccinia-Ig	Vaccinia Ig human	
90396	36	4	VZIg	VZIg	Varicella-zoster Ig human	CNII
	117	4	VZIG (IND)	VariZIG		CNJ
0000		1	Varicella IG	LVAGE	Lucia d'a ca	OVE
90665	66	Lyme	Lyme	LYMErix	Lyme disease	SKB
90735	39	Encephalitis	Japanese encephalitis-SC	JE-Vax	Japanese encephalitis-	JPN
	400	4	Innanan Franck 2011		Subcutaneous administration	
	129		Japanese Enceph, unspecified		Japanese Encephalitis vaccine,	
00700	104	-	formulation	lvioro	unspecified formulation	\/AI
90738	134		Japanese encephalitis-IM	Ixiaro	Japanese Encephalitis-	VAL
00705	0.5	NA I	Manalan	NA I	Intramuscular administration	MOD
90705	05	Measles	Measles	Measles	Measles live 1964-1974 (Eli	MSD
				Attenuvax	Lilly) Measles live	MSD
90708	04	-	Measles-Rubella	M-R-VAX	Measles and rubella live	MSD
90708	04		Iviedoleo-Rubella		ivicasies and fubella live	MSD
00704	07	Mumaa	Mumpo	Measles-Rubella (MERU)	Mumpo 1050 1079	
90704	07	Mumps	Mumps	Mumpsyay	Mumps 1950-1978	MSD MSD
90709		-	Rubella-Mumps, unspecified	Mumpsvax	Mumps live	INIOD
		1	formulation			
	38		Rubella-Mumps	Biavax II	Rubella and mumps live	MSD
		<u> </u>	1	Mumps-Rubella (MURU)		MSD
90707	03	MMR	MMR	MMR II		MSD
90710	94		MMRV	Proquad	Measles, mumps, rubella, varicella live	MSD
90733	32	Meningo	Meningococcal MPSV4	MENOMUNE	meningococcal polysaccharide vaccine (MPSV4)	PMC
90734	114	1	Meningococcal MCV4P	Menactra	meningococcal polysaccharide	PMC
					(groups A, C, Y and W-135) diphtheria toxoid conjugate	
	136	-	Meningococcal MCV4O	Menveo	vaccine (MCV4P) meningococcal oligosaccharide	SKB
					(groups A, C, Y and W-135)	
					diphtheria toxoid conjugate	
		1			vaccine (MCV4O)	
	147		MCV4, unspecified formulation		Meningococcal, MCV4, unspecified formulation(groups	
]			A, C, Y and W-135)	<u></u>
	108		Meningococcal ACWY, unspecified		meningococcal ACWY vaccine, unspecified formulation	
		1				
	148		Meningococcal C/Y-Hib PRP	Menhibrix	Meningococcal C/Y-Hib PRP	SKB
90644		1	Meningococcal, unknown		meningococcal vaccine of	
90644	167			Î.	unknown formulation and	ĺ
90644			serogroups			
	167	Maria D		Towns and	unknown serogroups	DEC
90644		MeningB	serogroups Meningococcal B, recombinant	Trumenba	unknown serogroups Meningococcal recombinant	PFR
	167	MeningB		Trumenba	unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B,	PFR
	167	MeningB		Trumenba	unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for	PFR
	167	MeningB		Trumenba	unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use	PFR
	167	MeningB		Trumenba	unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use Meningococcal B vaccine, fully	PFR
90621	167 162	MeningB	Meningococcal B, recombinant		unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use Meningococcal B vaccine, fully recombinant	
	167	MeningB		Trumenba BEXSERO	unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use Meningococcal B vaccine, fully recombinant Meningococcal recombinant	PFR SKB
90621	167 162	MeningB	Meningococcal B, recombinant		unknown serogroups Meningococcal recombinant lipoprotein vaccine, serogroup B, 3 dose schedule, for intramuscular use Meningococcal B vaccine, fully recombinant	

ccine, adjuvanted inspecified crine of n and second wall wall of the period of the per
Inspecified Sine of n and second wall wall wall wall wall wall wall wal
GRE oral WAL d IPV PMC ombination SKB mation PMC ion SKB mulation n-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
GRE oral WAL d IPV PMC ombination SKB ination PMC ion SKB ormulation h-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
GRE oral WAL d IPV PMC ombination SKB ination PMC ion SKB ormulation h-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
GRE oral WAL d IPV PMC ombination SKB nation PMC ion SKB imulation in-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
oral WAL d IPV PMC ombination SKB ination PMC ion SKB imulation in-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC pMC formulation t live oral 1999)
oral WAL d IPV PMC ombination SKB ination PMC ion SKB imulation in-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC pMC formulation t live oral 1999)
d IPV PMC ombination SKB ination PMC ion SKB ination PMC ion SKB imulation in-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
ombination SKB ination PMC ion SKB immulation N-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
Ination PMC Ion SKB Immulation In-US Ination PMC Ion SKB Immulation In-US Ination PMC Ion PMC Ion PMC Ion PMC Ion PMC Ion Ion PMC Ion Ion Ion PMC Ion Ion PMC Ion
ion SKB irmulation h-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
mulation n-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, cion pecified ar SKB PMC PMC formulation t live oral 1999)
n-US B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, cion pecified ar SKB PMC PMC formulation t live oral 1999)
B, historical saccharide WAL MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
MSD ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC PMC formulation t live oral 1999)
ugate WAL ugate PFR ugate, ion pecified ar SKB PMC PMC PMC formulation t live oral 1999)
ugate PFR ugate, ion pecified ar SKB PMC PMC formulation t live oral 1999)
ugate, cion pecified ar SKB PMC PMC PMC formulation t live oral 1999)
ugate, cion pecified ar SKB PMC PMC PMC formulation t live oral 1999)
pecified ar SKB PMC PMC PMC formulation t live oral 1999)
pecified ar SKB PMC PMC formulation t live oral 1999)
ar SKB PMC PMC formulation t live oral 1999)
PMC PMC formulation t live oral 1999) PMC WAL
PMC PMC formulation t live oral 1999) PMC WAL
formulation t live oral 1999)
formulation t live oral WAL 1999)
t live oral WAL 1999)
1999)
nt (after MSD
,
nt SKB
ed n
01/2006)
· ·
MSD MSD
live MSD
MSD
specified
.,
live MSD
MSD
PMC
dry WAL
diluted
eria adult PMC MBL
- CPT code PMC
nizations PMC
/2005 MBL
AKR
ria toxoids,
lult use
ed
DMO
PMC
SKB PMC
SKB
sorbed PMC
specified
specified
r /

CPT	CVX	Group	Vaccine	Trade Name	Description	MFG
90692	41		Typhoid, parenteral	Typhoid	Typhoid heat and phenol inactivated	
90693	53		Typhoid-AKD	Typhoid-AKD	Typhoid acetone-killed, dried (military)	
90714	91		Typhoid, unspecified formulation		Typhoid, unspecified formulation (after 7/1/2005, no CPT code is associated with this vaccine group)	
90710	94	Varicella	MMRV	Proquad	MMRV	MSD
90716	21	1	Varicella	Varivax	Varicella live	MSD
90717	37	Yellow Fever	Yellow Fever	YF-VAX	Yellow Fever live	PMC
90736	121	Zoster	Zoster (shingles), live	Zostavax	Zoster (shingles), live	MSD